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Purpose: Triamcinolone (TA) was commonly used for treatment of retinal diseases, 
especially promising for diabetic macular edema and exudative macular degeneration. 
However it has been recently shown to cause cytotoxicity on human retinal pigment 
epithelial (RPE) cells in culture. The present study aims to investigate whether cation 
channel blockers and openers can reduce the TA-induced cell death and affect the 
underlying mechanisms. 
Methods: Cultured human non-pigmented epithelial cells (ARPE19) were treated 
with TA(0.1mg/ml). Three concentrations of a calcium channel blocker, verapamil 
(VP, O.ljaM�l|_iM�lOjLiM), and a potassium channel opener, pinacidil (PIN, 0.1 |aM, 
IjiM, 10|iM), were given to pre-treat the cells prior to TA treatment. Samples of cells 
were harvested and studied on day 1, 3 and 5. The cell viability was verified using 
MTT assay. Expressions of a pro-apoptosis gene, caspaseS’ and two stress-response 
genes, c-jun, c-fos’ at different time intervals were investigated by reverse 
transcription-polymerase chain reaction. Production of caspaseS, c-jun and c-fos 
proteins was also investigated by immunofluorescence. 
Results: Reduction on cell viability was observed when cells were treated with TA 
O.lmg/ml, decreased by 64% compared with control on Day 1. The cell viability 
significantly increased on Day 5 in cells that have been pre-treated with PIN or VP 
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compared with administering TA alone. The expressions of caspaseS, c-jun, c-fos 
were all increased after TA treatment, but decreased if the cells had been pretxeated 
with PEN or VP. Results on the gene expressions obtained from RT-PCR and 
immunofluorescene were in general consistant. 
Conclusion: This study demonstrates that (1) The potassium channel opener pinacidil 
and the calcium channel blocker verapamil independently exert protective effect on 
RPE c ells against c ytotoxicity induced by TA. (2) The mechanisms o f c ytotoxicity 
involved appear to be complicated and include alterations in the expression of the 
pro-apoptotic gene caspaseS and early-response genes c-jun, c-fos. (3) Further work 
should study more specific agents such as diazoxide that targets the mitochondria 
KATP channel, and other kinase such as protein kinase C to further explore the 
mechanism. (4) Clinically, our results provide a new direction on the use of channel 
modulator to attenuate drug toxicity, where while animal models should be developed 
to further confirm the effect in vivo. 
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方法：ARPE19细胞经培养后用TA (0. Img/ml)进行治疗。三种浓度的钾离子 
通道开放剂(PIN 0. 1 U M, PIN 1 u M, PIN lOMm)和顿离子通道抑制剂(VP 0. 1 u M, 
VP 1 u M, VPlOuM)分别预先加入细胞，到底随后进行TA联合治疗，观察1，3, 
5天后细胞的变化。细胞活性用MTT来检测。调亡前基因caspase3和压力相关 
基因c - j u n , c-fos的表达通过逆转录-聚合酶链反应和免疫焚光染色来检测。 
结果：经过TA 0. Img/ml治疗后1天，细胞活性比对照组降低了 64%�第5天， 
经PIN或VP治疗过的细胞活性较单纯用TA 0. Img/ml治疗组显著提高。经TA 
治疗后，C 3 S P贴 c - j u n和 c _ f o s的表达增加，而联合 P I N或V P治疗后， 
这种增加的趋势减少；逆转录-聚合酶链反应和免疫突光染色的结果基本一致。 
结论：从本次研究结果发现，（1 )比起单纯用T A治疗，联合P I N或V P治疗 
能减轻TA导致的RPE细胞毒性。（2)内在的机制相当复杂，包括调亡前基因 
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1.1 Triamcinolone acetonide (TA) 
1.1.1 Application in ophthalmology 
Corticosteroids have important roles in their anti-inflammation, immunosuppression 
and anti-proliferation. Since its discovery in the early 1950s, the exploration of 
modification to the chemical structure for enhanced efficacy still continues. 
Triamcinolone acetonide (9a-fluoro-16a-hydroxyprednisolone, TA) is an intermediate 
acting corticosteroid in suspension form. It has been used as a potent anti-inflammatory 
agent for dermatological disorders (Michael and Robin, 1998; Brancaccio and Zappi, 
2000)，rhinitis (Hochhaus et al, 2002; Berge et al” 2003) and arthritis (Raynauld et aL, 
2003). Applications include systemic and topical. Precautions should be taken since 
prolonged and extensive use of TA often cause significant systemic side effects such as 
adrenal suppression, growth retardation. Gushing's syndrome and hypertension (Patrick et 
al.’ 2001). 
The application of TA in ophthalmology begins in the Nineteenth seventies. 
Successful therapeutic effects have been obtained in rabbit models (Tano et al., 1980; 
1981). It has been used as a potent anti-inflammatory agent for a number of ocular 
diseases, such as: conjunctivitis, keratitis, scleritis, iris, uveitis and retinitis. (Saini et al, 
1999; Zemir et al” 2002; Jonas et al., 2001; Darius et aL, 2002). The approach of drug 
delivery includes systemic and topical administration. Topical drug administration is 
employed in most situations for minimizing the systemic side effect. In recent years, there 
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have been reported in many clinical trials for exploring the management of various 
posterior segment diseases, especially the intraocular diseases, such as proliferative 
vitreoretinopathy (PVR) and intraocular neovascularization (Danis et al” 1996; Jonas et 
al., 2000; Martidis et al” 1999). Then question such as what is the optimal drug delivery 
approach to the target site followed. The intraocular injection of TA has received much 
attention since it provided the most direct route to delivering drugs to the tissues of the 
posterior segment, hence effective drug concentration can be achieved on specific sites. 
Its crystalline nature enabled prolonged duration of action lasting for several weeks. Jonas 
JB reported that 20mg TA could be maintained for up to 3 months after intravitreal 
injection (Jonas et al.’ 2001). Similar results were reported when patients received a 
single 4mg intravitreal injection of TA (Paul et al” 2003). Animal studies have also shown 
that the intravitreally-injected TA maintains a depot lasting 21-41 days (Schindler et al., 
1982; Scholes et al.’ 1985). Consequently, TA has been used successfully to treat in 
various ocular diseases in clinical treatment; such as it is a promising method for 
treatment of macular edema (Jonas et al,’ 2001; 2002; 2003; Martidis et al” 2002; 
Sheidow et al., 1998)，e specially diabetic macular edema since it is the main cause of 
poor vision in diabetic patients. It will be occurred in around 30% of patients who have 
been diabetes for 30 years. It was also used for treatment of exudative macular 
degeneration (Danis et al.，2000; Penfold et al., 2002)，scleritis and uveitis (Zemir et al” 
2002; Yoshikawa et al., 1995), neovascularisation (Ciulla et al., 2000; Jonas et al” 2001; 
Tano et al., 1980). Its clinical value was proven in reducing the incidence of retinal 
detachment after pars plana vitrectomy (Tano et al., 1980; Sakamoto et al.’ 2002; 
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Chandler et al” 1987) and assisting to completely separate the membrane from retina 
during pars plana vitrectomy (Taiji et al., 2002). 
1.1.2 Mechanism of anti-inflammatory effect 
TA plays major roles in the attenuation of inflammation, tissue edema and 
antiproliferation (Machemer et al., 1979; Jonas et al” 2001). Immunologically, the 
machanism of their anti-inflammatory action includes the drug's effect on both the 
number and function of lymphocytes, polymorphonuclear leukocytes, macrophages, an 
increase in vascular permeability and their capacity to inhibit pro-inflammatory cytokines 
interleukin-6 (IL-6), interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-alpha) 
(Schleimer et al., 1993; Lee et al” 1988) and to enhance the anti-inflammatory cytokine 
IL-10. Early studies indicated that glucocorticoids caused approximately one-third of 
decrease in number of macrophages in wounds compared to controls (Leibovitch and 
Ross 1975). They also suppress the release of TNF-a from monocytes and macrophages 
(Joyce et al., 1997b). There have been studies to investigate the capacity of TA to 
modulate the expression of adhesion molecules; its potential to influence the cellular 
permeability was further indicated in the treatment of age-related macular degeneration 
(Penfold et al, 2000; 2001). 
On the molecular level, the action of glucocorticoid hormones is mediated by their 
specific binding to the glucocorticoid receptors (GR) located in the cytoplasm. The 
activated hormone-receptor complex is then translocated into the nucleus for binding to 
specific hormone regulatory elements on the DNA and regulating expression of gene of 
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various activities such as the apoptotic gene caspaseS (Cidlowski et al., 1996; McKay et 
al., 1999; Webster et al., 1999). The interaction of the GR with activator protein (AP-1) 
and NF-Kb accounts for the clinically relevant anti-inflammatory and immunosuppressive 
properties of glucocorticoids (Ray et al, 1994; Hofmann et al., 1998). Recent study 
suggested the anti-inflammatory action of glucocorticoids was performed by two 
complementary mechanisms. On one hand, they induced death of the cells that provoke 
inflammation, and on the other hand they protect the resident cells of the inflamed tissue 
by arresting apoptotic signals (Amsterdam et al.’ 2002). 
1.1.3 Side effects ofTA 
Despite local application of TA can reduce its systemic side effects, there are still 
complications of concern. It can be attributed to the injection procedure or to the 
corticosteroid suspension. Potential injection-related complications include retinal 
detachment, vitreous hemorrhage, and endophthalmitis. Early study reported the 
intravitreally injected TA suspension was well tolerated by eyes of rabbits (Tano et al” 
1980; McCuen et al” 1981; Chandler et al., 1985; Hida et al.’ 1986) and primates 
(Ishibashi et al,, 1985). Two common ocular side effects attributed to intravitreal 
injection of TA are intraocular pressure (lOP) elevation and cataracts. In a series of 53 
patients with uveitis, the use of TA was associated with a significant rise in lOP in 36% of 
eyes, and glaucoma drainage surgery was required in more than 10% (Lafranco et al.’ 
1999). Intravirtreal TA, used in the treatment of age-related macular degeneration in 
patients, has also been associated with uncontrolled glaucoma and steroid cataract (Challa 
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et al” 1998). Wingate et al. have also reported that approximately 30% of patients 
developed a significant rise of lOP after intravitreal injection of TA (Wingate et al.，1999). 
Therefore, on the basis of above studies, caution should be taken in the use of TA via 
intravitreal injection in the treatment of ocular diseases. However, this side effect could 
be effectively managed since patients would be closely followed up and any sign of lOP 
elevation will be controlled by medication or paracentesis. 
Cataract is another common complication after intravitreal injection of TA. The first 
report about posterior subcapsular cataract associated with topical ocular corticosteroids 
appeared as early as 1963 (Valeric et al., 1963). A number of subsequent reported 
studies have confirmed this association (Lafranco et al.，1999; Challa et al.，1998; 
Wingate et al.，1999). Posterior subcapsular cataract can be observed following as little as 
4 months following topical corticosteoids (GCs) (McGhee et al.’ 2002). The progression 
of cataract was more rapid in subjects being intravitreally treated with TA than those 
without (Danis et al., 2000). 
1.1.4 Toxicity ofTA 
TA has been used in various ocular inflammatory diseases in experimental studies 
and clinical treatments. (McCuen et al., 1981, Machemer et al., 1979, Challa et al., 1998, 
Danis et al., 2000，Wingate et al, 1999). The cytotoxicity effect of glucocorticoids has 
long been known on lymphocytes (Munck et al., 1981). Another study to investigate the 
direct effects of TA at various concentrations on mouse fetal palatal mesenchyme cells 
showed that high level of TA (above 1 0 _ has the potential to interfere with mouse 
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palate formation by perturbing the proliferating activity and synthesis of macromolecules 
(Sasaki and Kurisu, 1983). A systematic comparison of the toxicity among halopredone 
acetate, TA and methylprednisolone acetate in mice and rats revealed severe toxic signs 
such as anemia, reduction of body weight gain when administered with TA or 
methylprednisolone acetate (Takeuchi et al, 1985). Similarly, Bunton and Plopper 
(Bunton and Plopper, 1984) reported retardation of the lung septa and body growth of the 
fetals when pregnant rhesus macaque's mother was given with TA. Results from ocular 
trials are controversial. One study reported up to 4mg of TA could be safely injected in 
silicone-filled, vitrectomized eyes without any significant retinal toxicity (Kivilcim et al.， 
2000). On the contrary, a study has indicated TA was cytotoxic on retinal pigmented 
epithelium cells and apoptosis might be involved in the mechanism of TA-induced cell 
death (Yeung et al., 2003). There is insufficient data to affirm the toxic effects. Therefore, 
it is necessary to further investigate the efficacy and toxicity of different doses of TA in 
details on ocular cells prior to animal studies. 
1.2 Retinal pigment epithelial (RPE) cell 
The retina is the innermost layer of the eyeball and it consists of an outer pigmented 
layer (RPE) and an inner neurosensory layer (Figure 1.2). The RPE extends forward from 
the margin of the optic nerve to the ora serrata (Figure 1.1). Its integrity helps to maintain 
the function of the retina. RPE degeneration, as a consequence of oxidative stress, is 
thought to be the pathogenesis of age-related macular degeneration (AMD) (Christen et 
al., 1999; Snodderly et al., 1995). 
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RPE consists of a single layer of cells separating the neural retina and the choroidal 
capillaries. The basal end of each cell is much infolded and rest s on a basement 
membrane, which forms part of Bruch's membrane of the choroids. The apical ends of the 
cell show multiple microvilli. There are plenty of potassium channels and calcium 
channels localized on the basal and apical ends of RPE (Hughes et al” 1996; Tao et al.� 
1994; 1995; Strauss et al” 1993; 2000; Shunji et al.’ 2001). Various metabolites are under 
bidirectional transport but the main flow of fluid is from the retinal side to the 
choriocapillaris, particularly for digested outer segment material from the photoreceptor. 
The role of the RPE as an outer barrier of the blood-retinal barrier is based on the 
presence of tight junctions (Penfold et al.，2000). This arrangement forms a barrier that 
limits the flow of ions and prevents diffusion of large toxic molecules from choroidal 
capillaries to the photoreceptors of the neural retina. An impairment of this barrier will 
attribute to the drusen formation (Ishibashi et al.’ 1986) and subretinal fluid accumulation, 
which leads to central serous chorioretinopathy, currently further thought to be associated 
with vascular abnormalities within the choriocapillaris (Prunte et al., 1996, Uyama 
M1999). 
The RPE cell is a multifunctional cell. It consists of plenty of melanin as well as 
various organelles, such as mitochondria, endoplasmic reticulum, Golgi and so on (Figure 
1.3). It also expresses many of the proteins that can be found in other cell types, thus it 
possesses several characteristic of common epithelial cells. When appropriately 
stimulated, RPE cells can synthesize and secrete growth factors such as FGF, IGF-1 (Cao 
et al., 1997) and IL-1 (Willermain et al., 2002) that most likely have a role in the normal 
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physiology of the retina. However, under pathologic situations this may contribute to 
conditions such as diabetic retinopathy and subretinal neovascularization. The RPE cell 
also contains a l and P2 adrenergic receptors (Moroi-Fetters et al., 1995; Frambach et aL, 
1990), plus enzymes of the cytochrome P450 drug-metabolizing system (Doyle et al., 
1995). 
The RPE has multiple functions (Schraermeyer U. and Heimann K . �1999) including 
keeping the integration of the blood- retinal barrier; participating the transportation of 
water and ion; scavenging free radicals; the absorption of light, participating in the 
turnover of the outer segments of the photoreceptors, and the formation of rhodopsin and 
iodopsin by storing and releasing vitamin A, which is a precursor of the photosensitive 
pigments. Its most important role is to maintain the physiology of photoreceptors, hence 
normal retinal function (Figure 3). 
1.3 Mechanism of cell death 
There are two major distinct modes of death in eukaryotic cells (Searle et al.，1982; 
Wyllie et al., 1980)，A) necrosis, in which the release of intracellular proteases and 
lysozymes induce an inflammatory response, B) apoptosis, where the cells quietly 
disappear as they are phagocytosed by surrounding cells (Figure 1.4). 
Cell death by necrosis usually follows major pathologically acute injury such as 
hypoxia, hyperthermia, viral invasion, exposure to various exogenous toxins, or attack by 
complements. It characterizes early mitochondrial swelling and failure, dysfunction of the 
plasma membrane with loss of homeostasis, cell swelling and rupture (Yuan et al,, 2003). 
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The loss of cell membrane integrity with release of cell contents, including proteases and 
lysozymes, induces an inflammatory response with cytokine release by the surrounding 
macrophages as they mop up the damaged cells and begin the process of repair (Lyonel et 
al” 1999). 
1.3.1 Apoptosis 
The major physiological mechanism of cell suicide is apoptosis. Apoptosis is a 
conserved process used by multi-cellular organism to eliminate redundant, infected, aged 
or damaged cells (Huettenbrenner et al.，2003). Derived from a Greek descriptive term for 
falling leaves or petals, it was first reported by Kerr et al. in 1972 to describe cell death 
responsible for tissue modeling in vertebrate development (Kerr et al., 1972). Apoptosis 
is now understood to be a vital tissue process necessary for development, homeostasis and 
effective immune system. Cells undergoing apoptosis present with morphologic change, 
such as ruffling, blebbing�and condensation of the plasma and nuclear membranes, 
subsequently, aggregation of nuclear chromatin. (Yeung et al., 2002; Lyonel et al” 1999). 
The feature of the end stage of apoptosis is endonuclease cleavage of DNA in the 
intemucleosomal linker regions, yielding 180-200 base-pair fragments (Arends et al.’ 
1990). The final events are executed by specific proteases (caspases), the disruption of 
cell structures and finally cell disassembly (Yuan et al., 1993). 
Endogenetic apoptosis occurs when elimination of surplus cells during 
embryogenesis, cell atrophy on endocrine withdrawal or loss of essential growth factors 
or cytokines, tissue remodeling and repairing, and removal of cells that have suffered 
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from genotoxic damage (Lyonel et al., 1999). Externally induced apoptosis occurs when 
cells are exposed to various forms of stimulus: such as ultra violet (UV) irradiation, 
mechanical stretch, G protein-coupled receptor agonist, growth factors, cytokines, 
stresses etc. Apoptosis in response to a variety of injurious stimuli has been demonstrated 
in several cells such as hepatoma and brain (Takano et al” 1991; Fukuda et al.，1993; 
Lennon et al., 1991; Reynolds et al. 1984, Tominaga et al., 1993). There are several 
pathways that will lead to apoptosis (Table 1.1): A) stress-induced apoptosis obtained by 
gene regulation, which mainly involves p53, Bcl-2/Bax and caspase. It characterized 
alteration of mitochondria including permeabilized outer membrane, releasing 
cytochrome C and other death-promoting proteins (Newmeyer and Ferguson-Miller, 
2003). B) cytotoxic regulation, which is a caspase-independent pathway responsible for 
removing pathogen-infected cells and tumor cells. C) Fas- Fas Ligand, which is through 
activation of "death receptors" expressed on the cell membrane (Gross et al” 1999; Cory 
and Adam 2002; Cory et al., 2003; Strasser et al” 2000; Lyonel et al.’ 1999). 
Glucocorticoids are known to induce apoptosis easily in the lymphoid tissue and 
brain (Cohen et al.’ 1984; Hassan et al., 1996; Murosaki et al” 1997). Delbert R 
demonstrated that corticosteroids produce apoptosis of airway epithelial cells in a 
time-dependent and concentration-dependent manner (Dorscheid et al.’ 2001). Hence the 
apoptosis-inducing characteristic of GCs is frequently used as a principal treatment of 
lymphomas (Haynes et al.’ 1990). This glucocorticoid-induced apoptosis is occurred 
through disruption ofmitochondrial membrane potential withrelease ofcytochrome C 
and other death-promoting proteins and the subsequent activation of caspase 9 and then 
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triggering the downstream caspase activation by effector caspase (Newmeyer et al.’ 2003; 
Dorscheid et al.’ 2001; Zou et al., 1998; Hu et al.’ 1999). Fas antigen might be partly 
related to apoptosis in TA-induced myopathy (Lee et al.’ 2001). It has been reported that 
glucocorticoids could change the membrane potential, hence changes in gene expression 
(Mann et al.’ 2001). Endoplastic reticulum (ER), as a major intracellular Calcium store, is 
receiving increased attention (Ferri and Kroemer, 2001; Kaufman et al” 2002). Although 
it was thought to participate in the stress-induced apoptosis, the precise mechanism is still 
unclear. Interventions to different levels of regulation have been performed in order to 
interfere the apoptotic process and further investigated the mechanism involved 
(Haraguchi et al., 2000; Hisahara et al” 2001). 
1.3.2 caspase 
Caspases are the main components responsible for apoptosis. The critical 
involvement of a cysteine protease CED-3 in apoptosis was first discovered in the 
nematode Caenorhabditis elegans in the mid-eighties (Yuan et al.’ 1993). Since then, 
compelling evidence has demonstrated that the mechanism of apoptosis is evolutionarily 
conserved, executed by a family of cysteine proteases that cleave after aspartate (Asp) 
residue in their substrates, hence the name caspase (Alnemri et a /.，1 996). At 1 east 14 
distinct mammalian caspases have been identified, although the first mammalian caspase, 
caspase-1 or ICE (interleukin Ip-converting enzyme), was identified to be an important 
regulator or inflammatory response. More than 8 of the 14 caspases play important roles 
during apoptosis (Budihardjo et al” 1999; Eamshaw et al” 1999; Fesik and Shi, 2001; 
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Salvesen and Dixit, 1997; Thomberry and Lazebnik, 1998). 
Caspases in apoptosis are generally divided into two categories, the initiator caspases, 
which include caspase-2, -8，-9，and -10，and the effector caspases, which include caspase 
-3，-6,and -7. An initiator caspase is characterized by a long N-terminal prodomain (>90 
amino acids), whereas an effector caspase contains 20-30 residues in its prodomain 
sequence. All caspases are produced in cells as catalytically inactive zymogens and must 
undergo proteolytic cleavage during apoptosis. The activation of an effector caspase is 
performed by an initiator caspase through cleavage at specific internal Asp residues that 
separate the large and small subunits. The initiator caspases, however, are autoactivated; 
activation is triggered by dimerization of the zymogen on a dedicated adaptor or scaffold 
protein Apaf-1 (Shi et al” 2002; Boatright et al” 2003). The activation of an initiator 
caspase in cells is closely regulated and often requires the assembly of a multicomponent 
complex under apoptotic conditions. For example, the activation of procaspase-9 is 
facilitated by Apaf-1 and cytochrome C (Zou et al., 1999)，which forms a � 1 . 4 Mda 
complex known as an apoptosome in the presence of dATP or ATP (Rodriguez and 
Lazebnik, 1999; Saleh et al,, 1999; Zou et al.’ 1999). A positive feedback loop was 
revealed in the cascade. Caspase 9 initiates the processing of caspaseS, and, conversely, 
caspaseS activates caspase 9. In the context of living cells, it is possible that this entire 
pathway reflects an amplification loop. By this model, upstream apoptotic signals may 
trigger mitochrondrial injury, resulting in cytochrome C release, I caspase 9 
activation, caspaseS activation, further mitochondrial damage, further cytochrome C 
release and so on. Apoptosome act as an amplifier of the caspase cascade rather than a 
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critical initiator in the above process (Marsden et al” 2002). 
Once activated, the effector caspases are responsible for the proteolytic cleavage of a 
wide spectrum of cellular targets, leading ultimately to cell death. The known cellular 
substrates include structural components (such as actin and nuclear lamin), regulatory 
proteins (such as DNA-dependent protein kinase), inhibitors of deoxyribonuclease (such 
as DNA fragmentation factor 45 (DFF45) or inhibitor caspase-dioXivdXQd. 
deoxyribonuclease (ICAD)，and other proapoptotic proteins and caspases (Thomberry and 
lazebnik, 1998). Multiple cytoprotective proteins are inactivated by caspases during 
apoptosis. For example, cleavage of the DFF45 leads to removal of its inhibition of 
DFF40 or caspase-activated deoxyribonuclease (CAD), which degrades the chromosomes 
into nucleosomal fragments during apoptosis (Enari et al.’ 1998; Liu et al.’ 1997; 1998). 
In recent study, caspaseS was employed to verify the induction of cell apoptosis because 
it was activated on the end stage of apoptosis as described above, hence it can most 
represent the status of apoptosis, on the other hand the previous work in our lab (Yeung et 
al., 2003) also suggested caspaseS can be the candidate gene to investigate the apoptosis. 
1.3.3 Mitogen-activated protein kinase (MAPK) 
Less than 15 years ago, researchers discovered novel protein kinases that interfered 
with mating pheromone-induced growth arrest and mating-induced cell fusion 
(Courchesne et al.’ 1989; Elion et al.’ 1990). Since then, this mitogen-activated protein 
kinases cascade was thought as one of the most common signal transduction systems and 
rapidly activated in responses to various stress stimuli such as cell proliferation, apoptosis, 
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migration, or gene expression (Hecquet et al., 2003; Nebreda et al.’ 2000; Wikinson et al., 
2000; Pearson et al” 2001). AP-1, a main transcription factor that can be activated by 
MAP kinases, is involved in the regulation of various cellular biological processes, 
together with MAP kinases (Ono et al” 2000; Karin et al.’ 1995; Shaulian et al” 2001). 
The MAPK superfamily is composed of three main and distinct signaling pathways: 
the extracellular signal-regulated protein kinases (ERKs), the c-jun N-terminal kinases or 
stress-activated protein kinases (JNK/SAPK), and the p38 family of kinases (Kim and 
Iwao, 2003; Stmiskova et al” 2002; Cowan et al., 2003). The ERK pathway is primarily 
responsible for growth factors and mitogens (Denhardt et al., 1996). JNK pathway and 
p38 are responsible for various stress signals (Irving and Bamford, 2002; New and Han, 
1998). Each of the MAPK pathways operates as a three-tier system (Figure 1.5). The 
MAPK, a serine/threonine kinase, is activated by its upstream kinase (MAPKK), which 
phosphorylates at both Ser/Thr and Tyr sites, targeting a Thr-X-Tyr motif on the MAPK 
(X is glutamate, proline or glycine for the ERK, JNK and p38 modules, respectively) 
(Hoeflich and Woodgett, 2001; Hagemaim and Blank, 2001). MAPK phosphorylation 
leads to a conformational change and a >1000-fold increase in specific activity. 
However, MAPKs are usually inactive unless phosphorylated by their respective 
upstream kinases (Hoeflich and Woodgett, 2001). Similarly, MAPKK is activated by its 
upstream kinase (MAPKKK) that receives signals from stimulus-activated receptors on 
the cell surface or through interactions with GTP-binding proteins and/or other kinases 
(MacKay et al., 1998; Cowan et al” 2003). At the end of these signaling cascades, the 
MAPKs phosphorlate their target proteins, many of which are nuclear proteins. It is well 
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known event that amino (N)-tenninal phosphorylation of c-jun at serines 63 and 73 by the 
jun N-terminal kinases (Binetmy et aL, 1991). 
The mechanism of the relationship between JNK and apoptosis is still unclear 
despite vigorous research. An early study reported that JNK pathway activated 
receptor-mediated apoptosis by induction of the Fas ligand in T lymphocytes (Paris et al., 
1998). More recently, the JNK pathway has been shown to be a direct activator of 
mitochondrial death machinery without other cellular components (Aoki et al.’ 2002). 
1.3.4 AP-1 
AP-1 is a homo-/heterodimeric complex composed of members of the Fos (c-Fos, 
FosB, Fral/2) and jun {c-Jun, JunD, JunB) families of transcription factors, which 
controls gene transcription by binding to AP-1 motifs present in regulatory regions of 
target genes (Kletsas et al.’ 2002). It is a crucial mediator of the early response of cells to 
extracellular stimuli (Shaulian and Karin, 2001; Angel and Karin, 1991; Karin et al, 
1997). After activation by a variety of agents such as mitogens, cytokines, hormones, or 
even electromagnetic radiation, the expression of AP-1-encoding genes stimulated by 
MAPK pathway is induced. Accordingly, AP-1 proteins accumulate and are subsequently 
activated by post-translational modifications, mostly phosphorylation (Karin et al” 1995; 
Karin et al.’ 1997; Kletsas et al” 2002). Both fos and jun proteins can also heterodimerize 
with other activating transcription factors, such as ATF-2; ATF-7; SMADs; Cbfa/runt, in 
regulation of a number of cellular processes (Whitmarsh and Davis, 1996; Munz et aL, 
2003; Qing et al.’ 2000; Hess et al., 2001). 
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Since c-jun and c-fos play important mediating roles in cells at their early response 
to external stress stimuli, it will be interesting to investigate whether they will be 
activated on TA treated RPE cells and their association with apoptosis caused by TA can 
induce RPE cells toxicity through the apoptosis pathway. 
1.4 Potassium channels (K+ channels) 
It is well known that movements of ions across the cell membrane regulate the cell 
activities. There are two ways for the ions to move across the membrane: transporters and 
specific ion channels. There are more types of K+ channel existing on the cell membrane 
than other types of ion channel (Rudy et al.’ 1988). It is present in virtually all cells of the 
body, from skeletal, cardiac and smooth muscles to neuronal and glandular tissues. 
Basically, the channel-forming protein consists four domains each of which contains 6 
(S1-S6) transmembrane alpha helices and a central ion pore (Figure 1.6). K+ channels are 
classified into 4 families: voltage-dependent; calcium-dependent; receptor coupled and 
others, which include ATP-sensitive channel (Standen N. B. and Quayle J. M., 1998). 
Each of 4 families is classified into several subtypes existing in specific tissues. 
ATP-sensitive K + channel (KATP) is a weakly inward-rectifying K + channel that is 
regulated by intracellular ATP and nucleoside diphosphates (NDPs). In the following 
section, KATP channel will be described in detail. 
1.4.1 Molecular structure of Ka tp channel 
On the molecular level, there are four groups of cloned inward rectifying K (Kir) 
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channel subunits until now: (1) Kir2.0/IRK subfamily, classical Kir channels (Takahashi 
et al.’ 1994); (2) Kir3.0/GIRK subfamily, G-protein-activated K+ channels (Isomoto et al.’ 
1996a); (3) Kir 1.0 and KIM.O/Kab subfamily. K+-transport K+ channels (Takumi et al” 
1995); and (4) Kir6.0/KATP subfamily, KATP channels (Inagaki et al., 1995a). In 1993，a 
KATP channel was cloned from the outer medulla of rat kidney (Ho et al” 1993). The 
primary structure of this Kir channel consists of two putative membrane-spanning regions 
(Ml and M2) and one potential pore-forming loop (H5) (Figure 1.6). KATP channel is 
composed of two distinct subunits: SUR and Kir. There are two Kir subunits belonging to 
KATP subfamily have been isolated so far: Kir6.1/u K A T P - 1 and K6.2/BIR (Inagaki et al., 
1995a; 1995b; Sakura et al.’ 1995). Kir6.1 is ubiquitously expressed in various tissues, 
while Kir6.2 is expressed in pancreas, heart, skeletal muscle, and brain (Inagaki et aL, 
1995a; 1995b). Both of Kir6.1 and Kir6.2 should couple with SURs to form functional 
KATP channels (Yamada et al” 1997; Inagaki et al., 1995a; 1995b; Cui et al., 2001). 
1.4.2 Regulation of KATP channel 
Effects of KATP channel modulators have been widely investigated on various tissues 
including cardiac muscle and other preparations in an attempt to elucidate their 
mechanism of actions. Two important drugs involve the modulation the activity of KATP 
channel is (1) potassium channel inhibitor, the antidiabetic sulfonylureas including 
glibenclamide and tolbutamide; (2) potassium channel openers (KCOs) including 
cromakalim, pinacidil, levcromakalim, nicorandil, diazoxide and minoxidil sulphate 
(Fujita et al., 2000). 
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In general, opening of K+ channels in cell membranes, with resulting increase in K+ 
conductance, shifts the membrane potential in a hyperpolarizing direction towards the K 
equilibrium potential (Bolton and Beech, 1993). Hyperpolarisation reduces the opening 
probability of ion channels involved in membrane depolarization and excitation is 
reduced by a direct action on the cell membrane (Andersson et al., 1992). The actions of 
KCOs are important in terms of their possible clinical therapeutic potential in the 
treatment of such conditions as hypertension, acute and chronic myocardial ischemia, 
asthma, urinary incontinence and certain skeletal muscle myopathies (Nichols and 
Lederer, 1991; Arena and Kass, 1989; Faivre and Findlay, 1989). KATP channels in 
different tissues display considerable variations in response to the presence of KCOs 
(Nelson and Quayle, 1995; Terzic et al.’ 1995; Nichols and Lederer, 1991; Ashcroft and 
Ashcroft, 1990). Recent studies suggest that mitochondria might also contain KATP 
channels (Mito- KATP) (Siemen et al., 1999; Grover and Garlid, 2000; Liu et al” 2001; Xu 
et al.’ 2002). They may play a role in ischemic neuronal death (Domoki et al., 1999; Liu 
et al” 2002). Recent study reported that MitoKAip channel openers inhibited apoptosis by 
preserving mitochondrial inner membrane potential (Teshima et al.’ 2003). Other study 
reported cytoprotective effect of KCOs was elicited by decreasing cytosolic and 
mitochondrial Ca^ "^  overload (Zaugg et al., 2003). 
1.4.3 Pinacidil (PIN) 
Pinacidil ((±)-N-cyano-4-pyridyl-N-1, 2，2-trimethyl-propyl-guanidine monohydrate) 
contains a single chiral carbon atom in its structure and is used clinically as the racemate 
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(Andersson et al.，1992). The relaxant activity of pinacidil is mainly due to the (-)-R 
enantiomer (Steinberg et al.，1991; Doggrell et al., 1995). Also, the (+)-enantiomer 
actually causes depolarization of the rat aorta (Doggrell et al., 1995). 
Pinacidil is one of a group of cyanoguanidine derivatives with antihypertensive 
properties in conscious dogs (Kawashima and Liang, 1985) and hypertensive patients 
(Carlsen et al.’ 1981). The site of action of pinacidil is located on the extracellular side of 
the cell membrane (Kwok and Kass, 1994). Recent study advances the concept that 
mitochondria also contain ATP-sensitive K+ channels (Siemen et al” 1999; Grover and 
Garlid 2000; Liu et al,，2001; Xu et al.’ 2002). Pinacidil increased the outward K"" current, 
hence hyperpolarized the cell membrane, which can be inhibited by glibenclamide and 
other KATP channel blockers (Itoh et al., 1992; Standen et al” 1989). It lowers blood 
pressure probably through direct vasodilatation (Ahnfelt-Ronne et al,’ 1988; Friedel and 
Brogden, 1990; Quast et al” 1992). It has been demonstrated that pinacidil, at high 
concentrations of K+ (>10 |iM), inhibits the arterial contractions (Nielsen and 
Arrigoni-Martelli, 1981; Mikkelsen and Lederballe Pedersen, 1982; Cook et al.，1988; 
Hermsmeyer et al” 1988; Videbaek et al” 1988b). Pinacidil has also been shown to impair 
transmitter release from the sympathetic innervation of the rat vas deferens, probably as a 
consequence of the opening of K channels (Soares-da Silva and Femandes, 1990). It has 
also shown to activate the Calcium-activated K+ channels at higher concentration (lOO^iM) 
in smooth muscle cells of the rat cerebral arteries (Stockbridge et al.，1991). At lower 
concentrations (l-20|xM), pinacidil also activated voltage-dependent K+ channel in human 
vascular smooth muscle cells (Bychkov et al., 1997). Sodium-Calcium ion exchange 
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pathway might in part be responsible for pinacidil-induced K+ channel-independent 
vasorelaxation (Tsang et al., 2003) (Table 1.2). 
In recent years, pinacidil was found to have cytoprotective effect in many conditions, 
such as ischemia and hypoxia (Grover et al., 1989)，in which mitoKAXp channels were 
demonstrated to playing a vital role. There are three main roles of mitochondrial K+ cycle 
in mitochondria and cell physiology: 1) provide volume homeostasis to prevent excessive 
matrix swelling; 2) provide volume regulation to prevent excessive matrix contraction 
and 3) regulate mitochondrial reactive oxygen species (ROS) production for the cell 
signaling (Garlid et al” 2003). Many studies demonstrated the Calcium ion overload was 
involved in the process of apoptosis (Lee et al” 2001; Graham and Che, 2001; McConkey 
et al.’ 1996)，while pretreated with high concentrations of KCO will prevent the 
mitochondria Calcium ion overload (Jovanovic et al” 1998; Jovanovic et al” 1999; 
Murata et al., 2001). It has been speculated that pinacidil may exert an inhibitory effect 
on the calcium sensitivity of the contractile machinery and that the relaxant effect of 
pinacidil may be due to a stimulatory effect on plasmalemmal calcium extrusion 
mechanisms but without affecting calcium accumulation in the sarcoplasmic reticulum 
(Meisheri et al,, 1990). The study carried out by Steinberg et al. (1988) suggested that 
pinacidil at high concentration (10|iM) specifically inhibited a2-mediated calcium influx 
when BHT 920 was used as the agonist. It is possible that pinacidil (and possibly other 
KCOs) may owe part of its effects due to action on the concentration of intracellular 
calcium ion (Iwamoto et al” 1993). 
Since pinacidil was widely applied in previous and recent studies. The characterictic 
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and function w as relatively known. Especially compelling studies have investigated its 
cytoprotective effect in various tissues; there is still no report on eye c ells, so we will 
investigate its effects on RPE cell. 
1.5 Calcium channel 
The calcium ion (Ca2+) is an important second messenger for intracellular signal 
transduction in all types of cells. The intracellular concentration of free Ca2+ is 
maintained at about 1/10,000 of the extracellular concentration in a resting condition 
(Somlyo et al” 1994; Ghosh et al” 1995). The low level of intracellular free C a � . enables 
the cells function as secretion and contraction. The maintenance of large gradient of Ca^ "^  
concentrations depends on three mechanisms: 1) the cell membrane, which consists of a 
Ca2+-impermeable lipid bilayer; 2) powerful systems to excrete Ca^ "*" to the extracellular 
space by Ca^^ (Ca^^-nH+ATPase) and Na+-Ca2+ exchanger; 3) intracellular organelles 
such as endoplasmic reticulum and mitochondria which are the component of intracellular 
storing system for the Ca^ "^  uptake (Borle et al” 1981). In general, intracellular free Ca^ "^  
increase can be obtained by rapid but transient Ca^^ release from intracellular Ca^ "^  stores 
and rather slow Ca^^ influx from the extracellular space. The Ca^^ influx by Ca^ "^  channels 
has been indicated to be especially important for regulation of Ca^^ concentration 
(Poelaert et al., 2000). Since voltage-dependent Ca^^ channels (VDCCs) play a very 
important role on the regulation of intracellular Ca^ "^  concentration, we focus on VDCCs 
in the following description. 
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1.5.1 VDCCs and subtypes 
Hagiwara first reported in 1975 that the possible existence of VDCCs in egg cell 
membrane of a starfish (Hagiwara et al.’ 1975). There are two classes of VDCCs: 
high-voltage-activated (HVA) and low-voltage-activated (LVA) Ca^^ channels (Figure 
1.7). The HVA Ca^^ channels are further divided into L-type, N-type, P/Q-type and 
R-type channels. LVA Ca channel only consists ofT-type channels. 
L-type VDCCs Ca channels are widely distributed in all types of cells except for 
platelets, their biophysical characteristics were first reported in 1985 using chick dorsal 
root ganglion neurons (Nowycky et al” 1985). The molecular structure of L-type channels 
in skeletal muscle consists of five different polypeptide subunits: the ai subimit, which 
forms the ion channel and contains Ca^^ antagonist binding sites (Tanabe et al” 1 987; 
Ellis et al., 1988); the a2 subunit, which does not contain any high-affinity binding site 
(Ellis et al., 1988) and three low-molecular-weight subunits, p，y and 6 (Ruth et al, 1989; 
Jay et al.’ 1 990) (Figure 1.8). The ai and p subunits contain phosphorylation sites for 
cAMP-dependent protein kinase (Takahashi et al., 1987). The function of the L-type Ca^ "^  
channel includes the generation of action potentials, signal transduction and 
recent-reported neurotransmitter secretion in the central nervous system (Kostyuk et al” 
1989; Bond et al.’ 1998; Protti and Llano 1998). 
1.5.2 Calcium channel blocker 
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A lot of clinically important drugs target the L-type Ca channel, such as 
dihydropyridines (i.e. nifedipine), phenylalkylamines (i.e. verapamil, gallopamil) and 
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benzothiazepines (i.e. diltiazem) (Table 1.3). All drugs bind to different sites of the L-type 
Ca2+ channels and hence reduce the influx of extracellular Ca^^ into the cell (Nayler et al” 
1991; Opie et al., 1987; Georg et al.’ 1998). Verapamil (VP) is the first clinically useful 
member of calcium channel blocker group. It originated from the attempts to synthesize 
more active analogues of papaverine that is a vasodilator. Since then, dozens of agents of 
varying structure have been found to have the same fundamental pharmacological action. 
Calcium channel blockers have been used in the therapy of hypertension, supraventricular 
tachyarrhythmias and various other conditions such as: hypertrophic cardiomyopathy, 
migraine, Raynaud's phenomenon, post-infarct tissue preservation, and atherosclerosis 
(Scriabine et al.’ 1987; O'Rourke et al” 1987; Taira et al.，1987; Weinstein et al., 1987). 
It is generally hypothesized that the cytosolic free Ca plays an important role for 
the control and the regulation of many cellular functions. For example, Kribben et al. 
(1994) using fUra 2 and rat renal proximal tubules (RPT) subjected to hypoxia 
demonstrated that intracellular Ca?^ levels increased significantly before cell death. In 
addition, Takano et al (1985) Wetzels et al. (1993) and Rose et al (1994) showed that 
decreasing the extracellular Ca^ "^  concentration reduced the release of lactate 
dehydrogenase from rabbit RPT subjected to anoxia and rat RPT subjected to hypoxia. 
1.5.3 Verapamil 
Verapamil is a member of voltage-dependent Ca^ "^  channel blockers. Effects of 
calcium channel blockers have been widely investigated on a variety of smooth muscle, 
cardiac muscle, skeletal muscle and other effects in an attempt to elucidate their 
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mechanism of actions. In general, the free calcium concentration elevations during 
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cellular activation may rise from two sources: Ca release from intracellular stores and 
Ca2+ influx across the plasma membrane. Binding of verapamil to the membrane receptor 
convert the mode of the channel operation from opening consistently after depolarization 
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to opening rarely, hence marked decrease in transmembrane Ca current, shifting the 
membrane potential in a hyperpolarizing direction. Hyperpolarisation reduces the opening 
probability of ion channels that are involved in membrane depolarization and followed by 
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long-lasting relaxation on the cell membrane. Based upon the above principle, Ca 
channel blockers have been used as cytoprotective agents against various forms of cell 
injury. For example, verapamil decreased cell death in rat RPT subjected to anoxia 
(Almeida et al.’ 1992; Rose et al., 1994; Wetzels et al” 1993). Furthermore, McCarty and 
O'Neil (1991) reported that rabbit RPT contains both a "base-line" verapamil-sensitive 
Ca2+ entry pathway and a nifedipine-sensitive Ca^^ entry pathway that is activated during 
regulatory volume decreases. Obatomi et al. (2001) demonstrated preincubation with 
verapamil or a sulphydryl-containing agent (DTT) provides protection against 
atractyloside-induced toxicity in renal cortical and liver slices in vitro. One study reported 
intraportal verapamil administration reduced the iscemia-reperfUsion injury caused by 
free oxygen radicals (Erdogan et al.’ 2001). Other study demonstrated verapamil exerts a 
protective effect against Ca^"^-induced mitochondrial damage by suppressing 
mitochondria Ca^ "^  uptake and mitochondria phospholipase activity (Koo et al” 1995). 
Cheng et al. (2003) reported simvastatin increases cytosolic free calcium concentration 
mainly through calcium influx from extracellular solution and then induce apoptosis by 
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activating caspaseS via calcium-dependent protease calpain. 
Based on above evidences, we hypothesize that TA-induced mitochondrial damage 
result in increased calcium, cytochrome C release, activate caspaseS, and then apoptosis 
may be inhibited by calcium channel blocker. Verapamil has been investigated as one of 
the most popular calcium channel blocker drugs group for several decades. Its 
cytoprotective e ffect was accounted in many recent studies; however, it is still unclear 
whether it is the same case on ocular tissues. 
1.6 Study objectives 
Previous study has shown TA to cause cycotoxic effects on cultured human RPE 
cells over time. Apoptosis might be involved in the mechanism of TA-induced cell death 
since increased caspaseS expression was detected. In cardiovascular system and urine 
systems, K+ channel opener and Ca^^ channel blocker are widely used as protective 
agents. In this study, we sought to investigate whether the concomitant administration of 
ion channel modulators (potassium channel opener and calcium channel blocker) could 
alleviate the unwanted cytotoxicity of TA on human retinal pigmented epithelium cell line 
in culture. We also attempted to investigate whether the cytoprotective effect of these ion 
channels modulator is related to the inhibition of proapoptotic gene (caspaseS) and stress 





A sagittal section view of the human eye with a schematic enlargement of the retina. 
Downloaded from website: hltp:// retina.umb.es/webvision/anatoniv.html 
The eyeball is made up of three different layers and three chambers of fluid. Three 
chambers of fluid: Anterior chamber (between cornea and iris), Posterior chamber 
(between iris, zonule fibers and lens) and the Vitreous chamber (between the lens and the 
retina). The external 1 ayer is formed by the sclera and comea. The intermediate 1 ayer， 
divided into two parts: anterior (iris and ciliary body) and posterior (choroid) .The 
internal layer, or the sensory part of the eye, the retina. 
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Figure 1.2 
A schematic diagram of retina. 
Downloaded from website: http://webvision.med.utah.edu/sretina.html 
The retina is highly organized in a number of layers. The pigment epithelium lies 
outermost in the retina, which is adjacent to the photosensor cells. 
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The relationship of the pigment cell to the outer segments of the rods and cones. RPE 
cells consist of plenty of melanin and various organelles; the apical ends of the RPE cell 
have multiple microvilli and envelope the outer segments of both rods and cones. 
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Table 1.1 Listing cell apoptosis related factors in different pathways 
Stress related pathway Death receptor cytotoxic regulation pathway 
pathway 
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Figure 1.4 flow chart of pathways of cell death 
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Figure 1.5 Flow chart of MAPK superfamily signal pathway 
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Figure 1.6 Illustration of potassium channel molecular structure, adapted from 
vvww.gcnoniehiolotr\.com/20()0/l/4/rcviews/0004/figijrc/Fl and 
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(a) Take Ky for example, the channel-forming protein consists of four domains each of 
which contains 6 (S1-S6) transmembrane alpha helices and a central ion pore, (b) The 
primary structure of this Kir channel consists of two putative membrane-spanning regions 
(Ml and M2) and one potential pore-forming loop (H5). 
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Table 1.2. Pathway of relaxant effects on common potassium channel openers 
Potassium channel Relaxant effects References 
openers 
Pinacidil KATP channel, Itoh et al. 1992 
calcium-activated K channel Stockbridge et al” 1991 
Voltage-dependent K channel Bychkov et al.’ 1997 
Sodium-calcium ion Tsang et al.’ 2003 
exchange pathway 
diazoxide KATP channel Yasushi et al., 2003 
cromaklalim KATP channel Sebille et al.’ 2004 
Sodium-potassium pump Hong et al., 1993 
levcromakalim KATP channel Criddle et al., 1994 
Voltage-dependent K channel 
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Table 1.3 Listing of characteristics of common calcium channel blockers 
L-type Calcium Effect of reduce Chemical Rate of side Protein 
channel blockers coronary blood structure effects binding (%) 
flow 
Verapamil Most potent phenylalkylamine 8-10% ^ 
nifedipine Potent 1,4-dihydropyridine 17-20% 90 
diltiazem Potent benzothiazepine 2-5% 78 
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Figure 1.7 Classification of VDCCs and subtypes 
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Figure 1.8 Illustration of calcium channel molecular structure, adapted from: 
vvvvw.cliemsoc.or<i/.../TiniSmitli/channels/calciii m 
The molecular structure of L-type channels consists of five different polypeptide 
subunits: the ai subunit, the a! subunit and three low-molecular-weight subunits, p, 




2.1 Cell biology 
2.1.1 Materials 
2.1.1.1 Culture related material 
Dulbeco's modified Eagle's medium with nutrient mixture F-12 (DMEM/F12), Hank's 
balanced saline solution (HBSS) and fetal bovine serum (FBS) were purchased from 
GIBCO (Rockville, MD). Penicillin/streptomycin and trypsin (type n ) were purchased 
from Sigma Chemistry Co. (St. Louis, MO, USA) and culture flasks and plates were 
purchased from Nunc IneterMed (Denmark). 
2.1.1.2 Drugs 
Triamcinolone acetonide was purchased from Bristol-Myers Squibb (Anagni, Italy) 
(Figure 2.1). Pinacidil were purchased from Sigma Chemistry Co. (St. Louis, MO, USA). 
Verapamil was purchased from Leo Pharmaceuticals (Germany). MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) was purchased from USB 
Co. (USA). Isopropanol was from Sigma. 
2.1.1.3 Cell line and instrument 
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Human non-pigmented epithelial (ARPE19) cell line was purchased from American 
Type Culture Collection (ATCC�Manassas, VA). Phase contrast microscropy was from 
Leica (Germany) (Figure 2.3). powerwave XS and attached software Kcjunior was from 
Bio-Tec instruments (USA). 
2.1.2 Preparations 
2.1.2.1Workmg medium 
Dulbecco's modified Eagle's medium with nutrient mixture F-12 (D-MEM/F12) in 
powder form was kept general stirring with 800ml Milli-Q water in a 1 L beaker at room 
temperature for about one hour. 1.2 g NaHCOs was added into the solution stirring until 
dissolved. The pH value was adjusted to 7.2 by IN NaOH or IN HCL, a little lower than the 
desired value 7.4 because there would be a 0.1- 0.3 rise in pH value upon filtration. Then the 
solution w a s m a d e up to 1 L. Themedium was filtered into a 1 L autoclaved glassbottle 
through the sterilized filter unit. 1 L blank medium was supplemented with lOOIU/ml 
penicillin and lOOmg/ml streptomycin, and 10% fetal bovine serum (FBS). 
2.1.2.2 Drugs 
Triamcinolone acetonide 
1ml Triamcinolone acetonide suspension (40mg/ml) was added to 39ml working 
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medium to obtain the stock concentration of Img/ml. This was then vortex mixed and, 
before the suspended TA particles settled down, diluted to obtain 0.Img/ml and 
0.0Img/ml of TA-containing culture medium. 
Verapamil and pinacidil 
Verapamil in powder form was dissolved in Milli-Q water to lO'^M as the stock and 
stored at 4° C. The stock was covered by aluminum paper since verapamil is light 
sensitive. Pinacidil in powder form was dissolved in 40% alcohol to lO'^M as the stock 
and kept at room temperature. Verapamil was serially diluted to 0.1 |iM, 1 | jM�and lOjiM 
with working medium to obtain one set of single drug-containing medium. The stock TA 
(Img/ml) was then added to serial concentrations of verapamil-containing medium to 
obtain another set of two drugs-containing medium (TA 0.Img/ml with serial 
concentrations of verapamil). All the processes of preparing verapamil were performed in 
the hood with light off. Same method was performed to prepare pinacidil except that the 
process could be done with light on. 
2.1.2.3 MTT solution 
MTT in powder form was dissolved in water to 5mg/ml as stock solution. To make 
10ml stock solution, 50mg MTT was added to HBSS. To make 10ml working solution 
(0.5mg/ml), added 1ml of MTT stock solution to 9ml blank medium. 
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2.1.3 Cell culture and treatment process 
2.1.3.1 Seed cell 
Human ARPE19 cells, within 5 passages from the time of purchase, were maintained 
in working medium. Cells were incubated at 37°C in 5%C02 /air and studied when 
confluence of cell growth was reached. After washed with HBSS, the cells were digested 
with 5 ml 0.05% trypsin solution and incubated 3 minutes in the hood. The digestion was 
stopped when the bulk of the suspension consisted of single cells and small clumps of 
cells by adding 5 ml of working medium to the digestion mixture. The suspension was 
transferred to a centrifuge tube and the cells were pelleted by centrifugation at 1300 rpm 
for 3 minutes. The cell pellet was re-suspended in the working medium and 5000 cells/ml 
was seeded onto three 24-well tissue culture plates (Figure 2.2). 16 wells divided to 4 
groups (control, O.Olmg/ml, O.lmg/ml and Img/ml) with 4 wells per group in each plate 
were used in preliminary study, the four concentrations were adopted based on that the 
volume of the vitreous chamber is 4ml and clinically used dosage. 20 wells in each plate 
were used in subsequent study. Since the method in this serial study is same, the 
following descriptions only focus on the subsequent study in detail. 
2.1.3.2 Treatment 
After overnight incubation, the seeded cells were washed gently with HBSS to 
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remove cell debris and unattached cells, fresh working medium was added and incubated 
for 1 hour, after removed the medium, two groups were pretreated with working medium 
(group 1 and group 2)，the other three groups were pretreated with ascending three 
concentrations of verapamil-containing medium respectively (group 3, group 4 and group 
5) for 30 minutes. Then the medium was removed again, the group 1 was treated with 
working medium, the group 2 was treated with TA O.lmg/ml, the group 3 was treated with 
TA O.lmg/ml and verapamil 0.1 |xM, the group 4 was treated with TA O.lmg/ml and 
verapamil l |iM, the group 5 was treated with TA O.lmg/ml and verapamil lOjxM (Table 
2.1a，b). The cells in three plates were incubated for 1，3 and 5 Days respectively based on 
the experience of confluence speed of RPE cells which will get to confluence within 5 
days. Cell morphology was taken by phase contrast microscopy. The same process was 
performed on pinacidil except the difference of light status. 
2.1.4 MTT-Cell Proliferation Assay 
The MTT-cell proliferation assay is a quantitative colorimetric assay for 
measurements of cellular proliferation, viability, and cytotoxicity (Mosmann, 1983; 
Denizot and Lang, 1986; Twentyman and Luscombe, 1987). After incubation of cells for 
1 day, one plate was taken out of the incubator, discarded the medium and added 200 
^1/well of the MTT solution (0.5mg/ml). The cells were incubated for additional 3 hr at 
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37°C and 5% CO2. The medium was discarded from the wells. Isopropanol was added to 
200|il/well to dissolve the formazan crystals. The solution was transferred to 96-well 
microliter plate and color intensity measured at 570nm (reference filter, 690nm) using 
spectrophotometer Powerwave XS. Measurement was repeated 3 times to get the mean 
absorbance value. The same process was performed on Day3 and Day5. 
2.2 Molecular biology 
2.2.1 Materials 
2.2.1.1 Chemicals, reagents, and kits 
p-Mercaptoethanol (P-ME), ethanol (absolute), lOmM dNTP Mix (lOmM each dATP, 
dGTP, dCTP and dTTP at neutral pH), 50mM MgCb, agarose, all were purchased from 
SIGMA, St. Louis, MO, USA. 1Kb DNA Ladder was purchased from GIBCO BRL. 
QIAShredder and RNeasy Mini Kit were from Qiagen (Valencia, CA, USA). 
2.2.1.2 Solutions and Buffers 
lOx PCR buffer: 20mM Tris-HCl (Ph 8.4)，SOmM KCl 
Agarose gel loading buffer: 0.25% bromophenol blue, 0.25% xylene cyanol FF and 30% 
glycerol 
Ethanol: diluted to 70% 
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Ethidium bromide: 0.25|xg/ml 
50x TAB buffer: 2M Tris-Acetate, 50mM EDTA�pH8.3 
5x First-Strand Buffer: 250mM Tris-HCl (Ph 8.3), 375mM KCl and 15mM MgCl2 
2.2.1.3 Primers and Enzymes 
Random primers (250ng/|xl), sense and antisense primers of 
glyceraldehydes-3-phosphate dehydrogenase (GAPDH), c-jun, c-fos, and caspaseS, 
superscript™ II Rnase H" Reverse Transcriptase (components including SuperScript™ II 
RT, 5x First-Strand Buffer, O.IM DTT), RNaseOUT™ Recombinant Ribonuclease 
Inhibitor (40 units尔 1) and Taq DNA polymerase (5 U/|il) were all purchased from 
Invitrogen Corporation (CA, USA). 
2.2.1.4 Equipment 
UV-Transilluminator at 309nm (UVP Inc., CA, USA) 
Gel Doc 2000 Video Gel Documentation System-Mac, 220/240 V (Bio Rad Laboratories, 
Hercules, CA, USA) 
GeneAmp® PCR System 9700 (PE Biosystems, Foster City, CA, USA) 
Nanodrop Spectrophotometer (Nanodrop Technologies Inc. USA) 
2.2.1.5 Software 
Quantity One® 4.0.3 (PE Applied Biosystems, Foster City, CA, USA) 
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Nanodrop 2.4.5 (Nanodrop Technologies Inc. USA) 
2.2.2 Reverse transcription - Polymerase Chain Reaction (RT-PCR) 
2.2.2.1 Cell collection and RNA Isolation 
Cells were seeded on four wells of 6-well plates. 8 plates were needed for 8 different 
time points of collection (0，10，20, 30，40，50, 60，90 minute from the time of exposing to 
drugs). Four wells of cells were treated as treatment process of group 2 to group 5，which 
was described in detail above. After incubate appropriate time period, the plate was taken 
out and washed with HBSS. 
RNeasy Mini Kit was used to isolation of total RNA from cultured cells. Cells were 
lysed with 350|il RLT buffer (P-ME was added to the RLT buffer before use), after 
complete homogenized, the lysates were pipeted directly onto a QIAshredder spin column, 
centrifuged the cell lysates for 3 minutes at maximum speed carefully transferred the 
supernatant to a new microcentrifuge tube by pipetting. Use only this supernatant (lysate) 
in subsequent steps. Added 350 jal of 70% ethanol to the cleared lysate, and mixed 
immediately by pipetting. Transferred 700 |xl mixture to an RNeasy mini column placed 
in a 2 ml collection tube (supplied). Closed the tube and centrifuged for 15 s at 10000 rpm. 
Discarded the flow-through, Added 700)11 buffer RWl to the RNeasy column. 
Centrifuged as the last step, and then transferred the RNeasy column into a new collection 
tube. Pipetted 500|il Buffer RPE onto the RNeasy column, centrifuged as the last step. 
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Another 500|il Buffer RPE was added to the RNeasy column, centrifuged for 2 minutes at 
13000 rpm. To elute, transferred the RNeasy column to a new 1.5 ml c ollection tube. 
RNeasy-free water was pipetted 30|il onto the RNeasy silica-gel membrane. Centrifuged 
for 1 minute at 10000 rpm repeated the elution step for high yield. Nanodrop with 
attached program was used to quantify RNA for three times. The absorbences at 
wavelengths of 260 nm and 280 nm were measured on the Nanodrop. The reading at 260 
run was used as the concentration of RNA; the ratio between reading 260 nm and 280 nm 
provides an estimate of the purity. In this study, the ratio was within 1.8-2.0. 500ng total 
RNA in individual sample was used to synthesize first-strand cDNA. 
2.2.2.2 Reverse Transcription (RT) 
The purpose of reverse transcription is to transcribe messenger RNA (mRNA) to first 
strand complementary DNA (cDNA). However, what we got using the above method was 
total RNA, it include mRNA, rRNA, cRNA. The mRNA with a long poly (A)+tail could 
be fished out from the total RNA sample by random primer. Reverse Transcription was 
achieved with SuperScript™ II Rnase H" Reverse Transcriptase (U.S.A.). 
500ng total RNA, dNTP Mix and l^il random primer were dissolved in RNease 
free water to 12|al. The mixture was incubated at 70°C for 10 minutes and immediately 
chilled on ice for another 5 minutes. Then the sample was mixed with 4|xl 5x First-Strand 
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Buffer, 2|al O.IM DTT, 1 [il RNaseOUT™ Recombinant Ribonuclease Inhibitor and 1^1 
(200 units) superscript™ IIRT. Incubated the sample at 25°C for 10 minutes, 42°C for 50 
minutes and 70°C for 15 minutes. Then the cDNA could now be used as a template for 
amplification in PGR. It should be stored at -20°C. 
2.2.2.3 PGR Reaction 
Primers used for PGR Reaction 
cDNA sequences of early response gene c-jun, c-fos, and proapoptotic gene 
caspaseS were specially designed. The specific primer sequences of housekeeping gene 
GAPDH were: 5，-gaa ggt gaa ggt egg agt-3，(sense) and 5'-gaa gat ggt gat ggg att tc-3’ 
(antisense), with expected cDNA of 227bp. The specific primer sequences of c-jun were: 
5'-gtg acg gac tgt tct atg act g-3’ (sense) and 5，-ggg ggt egg cgt ggt ggt gat g-3， 
(antisense), with expected cDNA of 297bp. The specific primer sequences of c-fos were: 
5,-aga cag acc aac tag aag atg a-3，(sense) and 5'-age tct gtg gcc atg ggc ccc-3, 
(antisense), with expected cDNA of 457bp. The specific primer sequences of caspaseS 
were: 5'-tat tct tgg gga aat tea aag gat-3，(sense) and 5'-aaa gta gcg tea aag gaa aag gac-3' 
(antisense), with expected cDNA of 158bp. 
General procedures of PGR 
The polymerase chain reaction (PGR) is a method to selectively and rapidly replicate 
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a given nucleotide sequence in large amounts from any DNA that contains it. From it was 
invented in 1983; it received great attention and now was widely used in diagnostic tests 
for disease genes. PCR is based on the use of DNA polymerase to copy a DNA template 
in repeated rounds of replication. The amplification of DNA involves a repetitive series of 
temperature cycles that can be divided to 3 steps on each cycle. Denaturation of the 
template DNA to separate the double-strand, then cooling of the DNA allows primers to 
anneal to the complementary sequences in the two template DNA strands, finally, this 
mixture is then incubated with DNA polymerase and the four deoxyribonucleoside 
triphosphates to extend the primers so that DNA is synthesized. 
In this study, PCR was used to test the expression of gene GAPDH, c-jun, c-fos, and 
proapoptotic gene caspaseS. l}xl of cDNA template from the first-strand reaction was 
mixed with 2.5|xl of lOx PCR buffer, O.S i^l lOmM dNTP mix, LSjil MgCh (l.O^il MgCh 
for gene GAPDH), 0.3|il of 10|iM of each sense and antisense primers, 0.1 |xl of Tag DNA 
polymerase and autoclaved Milli-Q water up to a total of 25|j1 The condition of PCR 
amplification was as follows: denaturation temperature was at 95°C for 40 seconds; 
annealing temperature of GAPDH was at 60°C for 1 minute, the other three gene 
annealed at 58°C for 1 minute. Extension temperature was at 72�C for 40 seconds. 
Amplification were Performed on theraiocycler, ran 20 cycles for GAPDH and 30 cycles 
for other three genes. After PCR, centrifuged samples briefly and stored samples at 4°C. 
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DNA Gel Electrophoresis 
Gel electrophoresis was performed to semi-quantified the concentration of the target 
gene by measuring the density of the band. DNA gel (2%) was prepared by mixing 1.0 g 
agarose with 50 ml Ix TAE and boiling to dissolve agarose. Cooled the mixture at room 
temterature for 15 minutes, Ethidium bromide was added to the mixture before the 
solidification of the gel. The gel was set in a 48-well gel setter until cool down. Then it 
was put in a gel tank containing sufficient Ix TAE running buffer. The volume ratio of 
DNA sample and loading dye added into each well was 5: 2. 1.5|il 1Kb marker was used 
to analyze the PCR product. The gel tank was connected to the power supply; DNA 
nucleotide carried negative charges would migrate to the anode in the presence of 
electrical field. The running time was between 12-15 minutes at 100 volt for each 
experiment. The bands were visualized under UV transilluminator at 309nm. Photographs 
were taken with a Gel Doc 2000 and analyzed using the software Quantity One® 4.0.3. 
The densities of the bands of c-jun, c-fos and caspaseS were normalized to GAPDH 
(Yeung et al” 2003). 
2.3 Immunocytochemistry 
Immunocytochemistry is the method of choice for locating an antigen to a particular 
structure or subcellular c ompartment provided that an antibody specific for the protein 
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under study is available. Immunoflurescence is a sensitive method requiring only one 
available antigenic site on the protein, it can be used for identifying cytoskeletal structure 
and organelles, building up a biochemical or protein chemical anatomy of a structure and 
demonstrating the heterogeneity in mixed cells. 
2.3.1 Materials and instrumentation 
2.3.1.1 Antibodies and Equipment 
Primary antibodies of c-jun, c-fos and active caspaseS protein (Santa Cruz, CA, 
USA) and secondary antibodies coupled to 4，，6‘-diamino-2-penylindole (DAPI) was 
purchased from Amersham (Biomaker, Dako, Sigma, USA). Fluorescence and light 
microscopes (Carl Zeiss, Oberkochen, Germany) 
2.3.1.2 Chemicals and other useful items 
Camptothecin, HEPES, Paraformaldehyde, NaHCOs, NaOH, NH4CI, Methanol, 
Saponin, bovine serum albumin, TxTW, Moviol, HCl, acetone, phosphate-buffered saline 
(PBS) and Round (12-mm) glass coverslips, metal racks, glass disk, glass beaker. 
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2.3.2 Preparations 
2.3.2.1 Preparation of coverslips 
Put the coverslips in 1 N HCl for 30 minutes; took out and washed with Milli-Q 
water for 3 times; put it in acetone for another 30 minutes; washed with Milli-Q water for 
3 times; transferee! the coverslips to metal racks in incubator at 70 °C until it dried. 
Transferee! it to a glass disk covered with tin foil and dried heat in incubator at 150°C 
paraformaldehyde for 4 hours. 
2.3.2.2 Prepations of solutions 
Camptothecin (10'^ M): added 0.5mg camptothecin powder to 50ml NaOH (1 N) to 
obtain the concentration of 10"^  M, then added 10 \i\ to 10ml Milli-Q water. 
HBSS-HEPES (20 mM): to make 5 00ml，added 0.175g NaHCOs and 2.35g HEPES to 
500ml HBSS, mixed and filtered before use. 
3% paraformaldehyde: to make 50ml, added 1.5g paraformaldehyde to 50ml 
HBSS-HEPES, heated to 70°C, added IN NaOH and stirred until the solution were clear. 
All the above process was done in the hood. Cooled down until ambient temperature, 
adjusted the pH to 7.4，filtered before use. 
NH4CI (50mM): to make 40ml, 0.107g NH4CI in powder form was diluted by distilled 
water. 
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10% fetal bovine serum (FBS): diluted the FBS in PBS. 
1% BSA: to make 100ml, added Ig BSA powder to 100ml PBS. 
Permeabilization and blocking solution (0.15% Saponin, 0.1% BSA): 
To make 30ml, added 0.045g Saponin and 3ml 1% BSAto 27ml PBS. 
Solution for dilute antibodies (0.0015% TxTW, 1% BSA, 0.425% Saponin): 
To make 30ml, prepared 0.15% TxTW first, added 15|il tweens and I5\i\ triton to 10 ml 
PBS, then added 0.1275g Saponin and 300|il 0.15% TxTW to 30ml PBS. 
2.3.3 Procedures 
Cells were seeded on coverslips. Cell culture was performed as previous described. 
Cells in 7 wells were treated, one was for control, one was for negative control, the 
remaining five wells were 10'^  M camptothecin, which is a positive control (Martelli et al., 
1999), O.lmg/ml TA and concomitant application of three concentrations of verapamil 
plus TA. After incubated for 2 days, washed the cells and fixed in 3% paraformaldehyde 
for 5 minutes, then diluted the fixative to 0.5% and fixed for another 30 minutes at 
ambient temperature. Rinsed coverslips 3 times with HBSS-HEPES, then placed samples 
in 50mM NH4CI for 30 minutes on ice. Rinsed coverslips 3 times with HBSS-HEPES, put 
samples to ice-cooled methanol for 1 minute, directly put samples to 10% FBS for 20 
minutes, and then washed with PBS to ambient temperature. Cells were permiabilized in 
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0.15% Saponin, 0.1% BSA for 15 minutes. Primary antibody of caspaseS made in mouse 
was diluted to 1:100 in 0.0015% TxTW, 1% BSA, 0.425% Saponin, and incubated the 
samples at room temperature for 2 hours. Coverslips were washed with 0.1% BSA for 3 
times. Secondary antibody of anti-mouse was diluted to 1:1000, 1:2000 DAPI were also 
added, incubated the samples covered with tin foil at room temperature for 45 minutes. 
Coverslips were washed with 0.1% BSA for 3 times. Then put in PBS for 3 minutes, and 
then washed coverslips in distilled water shortly, finally, mounted in moviol. The slides 
were stored at - 4°C in darkness. 
When the moviol got solid, the slides could be viewed under immunofluorescence 
microscopy through appropriate filters, such as green filter for cytoplasm, blue filter for 
nuclei. Photos could be taken by advance spot system. The other two antibodies followed 
the same procedures. Procedures of experiment on pinacidil were performed like 
verapamil. 
2.4 Expression of results and statistics 
The results of MTT Assay were expressed as mean 士 SD. The difference between 
control and other four treatment groups were analyzed using ANOVA, as well as the 
difference of vial cell number over time. 
The results of gene expression were expressed as density of band normalized to 
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background and GAPDH. The difference b etween four treatment groups o ver difFerent 
time point was compared with ANOVA. Immunofluorescences were showed as 
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Image of triamcinolone. 
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Figure 2.2 
Image of 24-well plate with 5000 cells/well. 
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Figure 2.3 
Image of phase contrast microscopy. 
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Table 2.1a Study design 
Group 1 Group 2 Group 3 Group 4 Group 5 
Working medium T A O.lmg/ml P I N O . L J I M + T A P I N 1 M M + T A P I N 1 0 ^ I M + T A 
V P O . L ^ I M + T A V P L^IM + T A V P 1 0 | I M + T A 
Table 2.1b Study design 
Cell viability assay Gene expression Immunofluorescence 






3.1 Effects of TA on RPE cell culture 
3.1.1 Cell morphology 
After exposing RPE cells to TA, there are a lot of randomly distributed TA particles 
could be seen on the top of the RPE cells. Cells were more flattened in monolayer in the 
presence of TA O.Olmg/ml and control while they were oval and of reduced size in the 
presence of TAO.lmg/ml and Img/ml (Figure 3.1). 
3.1.2 MTT assay 
MTT assay was performed on day 1，day 3 and day 5. A significant decrease in 
viable cell numbers was observed when the cells were treated with TA O.lmg/ml and TA 
Img/ml compared with TA O.Olmg/ml in all three days (all pO.OOl) (Figure 3.2). There 
is no difference in cell numbers between groups TA O.lmg/ml and TA Img/ml. The viable 
cell number was increased in linear maimer over three days period whatever the 
treatments were given. 
3.1.3 Gene expressions 
Semiquantification of gel band intensity shown the caspaseS expression significantly 
increased on 1 0, 2 0 and 30 m inute after the cells w ere t reated with TA 0.1 mg/ml a nd 
Img/ml compared with control or TAO.01 mg/ml (p<0.001; p<0.001; p =0.002) (Figure 
3.3). The trend of the increase slight reduced to normal level from 40 minute. There is no 
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difference on 20 and 30 minute between the cells were treated with TA O.lmg/ml and TA 
Img/ml. Similarly, no difference was shown on 10, 20 and 30 minute between the cells 
were treated with TAO.OImg/ml and control. 
Semiquantification of gel band intensity of c-jun expression significantly increased 
on 10，20 and 30 minute after the cells were treated with TA O.lmg/ml and Img/ml 
compared with control or TA O.Olmg/ml (p=0.001; pO.OOl; p<0.001) (Figure 3.4). 
Semiquantification of gel band intensity shown the c-fos expression significantly 
increased on 1 0, 2 0 and 3 0 minute after the cells were treated with TAO .Img/ml and 
Img/ml compared with control or TA O.Olmg/ml (all p<0.001) except that there is no 
difference of c-fos expression between the cells were treated with TA O.Olmg/ml and TA 
O.lmg/ml on 10 minute (Figure 3.5). 
There is no protein expression of caspaseS by immunofluorescence. The intensity of 
c-fos and c-jun expression increased when the cells were treated with TA O.lmg/ml and 
Img/ml compared with control and TA O.Olmg/ml (Figure 3.6, 3.7). There is no obvious 
difference of intensity on RPE cells between higher two concentrations of TA as well as 
TA O.Olmg/ml and control. 
3.2 Effects of PIN/VP on TA treated RPE cells 
3.2.1 MTT assay 
The cellular viability under treatments with TA + PIN increased more obviously over 
time compared with TA alone. There is no difference among groups in the presence of TA 
on Dayl and Day3. However, the cell viability significantly increased on Day 5 in cells 
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that have been pre-treated with PIN 0.1 |iM (p=0.009, n=4)，l^iM (p=0.004, n=4) and 
lOjiM (p<0.001, n=4) compared with administrating TA alone. A more protective effect 
was observed when the cell was pre-treated with PIN at lOjiM than at 0.1 p-M and l|aM 
(p=0.02 and p=0.042). There is no difference between the cells pre-treated with PIN 
0.1 jaM and PIN l^iM on Day5 (Figure 3.8). 
The cellular viability under treatment with TA +VP increased time-dependently and 
more obviously compared with TA alone. There is also no difference among groups in the 
presence of TA on Dayl and Day3. Cells pretreated with all three concentrations of 
verapamil significantly increased cell viabilities on Day5 compared with using TA alone. 
(p=0.008, n=4; p=0.002, n=4 and p<0.001, n=4 respectively). There is also no difference 
among groups pretreated with three concentrations of VP on Day5 (Figure 3.9). 
3.2.2 Gene expression 
3.2.2.1 Expression of housekeeping gene 
All cells, whatever treatment was given or not, showed similar GAPDH expressions 
in 500ng of total RNA. 
3.2.2.2 Expression of apoptosis-related gene 
Since caspase plays important role in cell apoptosis after TA treatment. 500ng of 
total RNA of caspaseS was amplified, and the level of DNA expression varied with time 
and application of ion c hannel m odulators. A s p revious s tudy s hown, the upregulation 
time for responding to TA treatment is at about 30 minutes, and then gradually reducing to 
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basal level at 60 minutes. When the cell was pretreated with pinacidil, the expression of 
caspaseS was reduced at all timepoints accordingly. But the difference in caspaseS 
expression cannot reach the statistically significant between the cells treated with TA and 
pretreated with pinacidil 0.1 |aM and l|iM. When the cells pretreated with pinacidil 10 [iM, 
the caspaseS expression of various timepoints are all atbaseline levels, while i t reach 
significantly different compared with other three treatments only at 40 minute (p=0.012) 
(Figure 3.10). The cells pretreated with verapamil shown similar trend of caspaseS 
expression, while the expression significantly decreased at 30 and 40 minute when the 
cells were pretreated with lOjiM verapamil compared with TA alone (p=0.03, p=0.04) 
(Figure 3.11). 
3.2.2.3 Expression of early-response genes 
c-fos and c-jun are major components of transcription factor AP-1, which plays an 
important part in cell apoptosis. In this study, the level of c-fos expression in RPE cells 
increased at about 10 minutes after treated with TA, and quickly reduced to basal level at 
about 30 minute. The c-fos expression on cells pretreated with pinacidil 0.1 |iM did not 
show any difference from that of treated with TA alone, while c-fos expression 
significantly decreased when the cells were pretreated with pinacidil \\iM and 10|iM 
compared with the cells being pretreated with pinacidil 0.1 jiM at 20 minute (p=0.031). 
There are no difference of c-fos expression between the cells, which were pretreated with 
pinacidil l|aM and lOjiM (Figure 3.12). On the other hand, the level of c-jun expression in 
RPE cells increased at about 20 minutes after treated with TA, and quickly reduced to 
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basal 1 evel at about 30 m inute. The c-jun e xpression o n e ells p retreated w ith p inacidil 
0.1 |iM and 1 [iM did not show any difference from the cells treated with TA alone, c-jun 
expression decreased when the cells were pretreated with pinacidil lOjaM though don't 
reach the statistically significant different (Figure 3.13). 
When the cells were pretreated with verapamil, the c-fos expression according to 
various time points on cells pretreated with verapamil 0.1 did not show any difference 
from treated with TA alone, while c-fos expression significantly decreased when the cells 
were pretreated with verapamil l|xM and verapamil lOjiM compared with the cells being 
pretreated with verapamil 0.1 jiM and treated with TA alone at 10 and 20 minute (p=0.035, 
p= 0.031) (Figure 3.14). On the other hand, the c-jun expression on cells pretreated with 
verapamil 0.1 |iM and l|xM did not show any difference from the cells treated with TA 
alone, c-jun expression decreased when the cells were pretreated with verapamil 10|iM 
though don't reach the statistically significant different (Figure 3.15). 
3.2.3 Immunofluorescence 
Immunofluorescence can effectively locate the antigen to a specific cell 
compartment by binding to a specific antibody. There is no protein expression of 
caspaseS in RPE cells by immunofluorescence. However protein expression of c-fos and 
c-jun in cytoplasm and nuclear can be observed in cells after treated with TA whatever 
pretreated with pinacidil or verapamil or not. There are no expression of c-fos and c-jun in 
cells without any treatment. Figure 3.16 shows the intensity of c-fos expression when the 
cells received different treatment strategies. When the cells were pretreated with pinacidil 
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l}j.M and 10|xM, the intensity of c-fos expression was reduced greatly compared with the 
cells pretreated with pinacidil O.ljxM. When the cells were pretreated with various doses 
of verapamil, the intensity of c-fos expression was reduced compared with the cells 
treated with TA alone. There is slightly difference between the different concentrations of 
verapamil, it seems the intensity of c-fos expression was slightly decreased when the cells 
were pretreated with verapamil l|iM and 10|iM compared with 0.1 jiM (Figure 3.17). 
Figure 3.18 shows the intensity of c-jun expression when the cells received different 
treatment strategies. When the cells were pretreated with pinacidil lOjxM, the intensity of 
c-jun expression was reduced compared with the cells pretreated with pinacidil 0.1|j-M, 
l^iM and treated with TA alone. However, the intensity of c-jun expression seems reduced 
when the cells were pretreated with verapamil, especially the higher concentration of 
verapamil (lOjiM) (Figure 3.19). 
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Figure 3.1 
Cell morphology in the presence of different concentrations of TA (control, TA 
O.Olmg/ml, TA O.lmg/ml and TA Img/ml). Cells were more flattened in monolayers in 
the presence of TAO.Olmg/ml and control while they were oval and of reduced size in the 
presence of TAO.lmg/ml and Img/ml. 
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Figure 3.2 
The viability of RPE cells in the presence of different treatment strategies (TA 
alone, TA O.Olmg/ml, TA O.lmg/ml and TA Img/ml) for day 1，day 3 and day 5. On 
all three days, a significant decrease in viable cell numbers was observed when the cells 
were treated with TA O.lmg/ml and TA Img/ml compared with TA O.Olmg/ml (*** 
p<0.001，•••pO.OOl，### pO.OOl). There is no difference in cell numbers between 
groups TA O.lmg/ml and TA Img/ml. 
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Figure 3.3 
Semi-quantification of PCR band intensity of caspaseS normalized with GAPDH 
at different time points when the cells were treated with different treatment 
strategies (TA, TA O.Olmg/ml, TA O.lmg/ml and TA Img/ml). The caspaseS 
expression was significantly increased on 10，20 and 30 minute after the cells were 
treated with TA O.lmg/ml and Img/ml compared with control. 
•• p<0.05, ***p<0.001 
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Figure 3.4 
Semi-quantification of PGR band intensity of c-jun normalized with GAPDH at 
different timepoints when the cells were treated with different treatment strategies 
(TA, TA O.Olmg/ml, TA O.lmg/ml and TA Img/ml). The c-jun expression was 
significantly increased on 10，20 and 30 minute after the cells were treated with TA 
O.lmg/ml and TA Img/ml compared with control. 
** p<0.05, ***p<0.001 
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Figure 3.5 
Semi-quantification of PCR band intensity of c-fos normalized with GAPDH at 
different time points when the cells were treated with different treatment 
strategies (TA, TA O.Olmg/ml，TA O.lmg/ml and TA Img/ml). The c-fos expression 
was significantly increased on 10，20 and 30 minute after the cells were treated with TA 
O.lmg/ml and TA Img/ml compared with control. 
** p<0.05, ***p<0.001 
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Figure 3.6 
C-fos expression on the presence of the different concentrations of TA (control, TA 
O.Olmg/ml, TA O.lmg/ml, TA Img/ml). When the cells were treated with TA O.lmg/ml 
and TA Img/ml, the intensity of c-fos expression was increased greatly compared with the 
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Figure 3.7 
C-jun expression on the presence of the different concentrations of TA (control, TA 
O.Olmg/ml, TA O.lmg/ml, TA Img/ml). When the cells were treated with TA O.lmg/ml 
and TA Img/ml, the intensity of c-jun expression was increased greatly compared with the 
cells treated with control or TA O.Olmg/ml. 
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Figure 3.8 
The viability of RPE cells in the presence of different treatment strategies (TA alone, 
TA + PIN 0.1 nM, TA + PIN l^M and TA + PIN 10 ^M) for day 1，day3 and dayS. On 
day 5，significant increase in cell numbers was observed when the cells were pretreated 
with PIN at all concentrations. A more protective effect was observed when the cell was 
pre-treated with PIN at lO^iM than at 0.1 ^ M and l|iM (*** p<0.001 vs TA alone; ### 
pcO.OOl v^TA+PIN O.l^M andTA + PIN 1 _ . 
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Figure 3.9 
The viability of RPE cells in the presence of different treatment strategies (TA alone, 
TA + VP O.ljiM, TA + VP IjiM and TA + VP 10 \iM) for day 1, day3 and dayS. On 
day 5, significant increase in cell numbers was observed when the cells were pretreated 
with VP at all concentrations. (*** pO.OOl V5 TA alone). 
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Figure 3.10 
Semi-quantification of PGR band intensity of caspaseS normalized with GAPDH at 
different time points when the cells were treated with different treatment strategies 
(TA alone, TA + PIN 0.1 |iM, TA + PIN l^iM and TA + PIN 10 When the cells 
pretreated with pinacidil 10 the caspaseS expression of various time points was 
decreased to baseline levels，while reach significantly different compared with other 
treatment strategies at 40 minute. 
p<0.05 
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Figure 3.11 
Semi-quantification of PCR band intensity of caspaseS normalized with GAPDH at 
different time points when the cells were treated with different treatment strategies 
(TA alone, TA + VP 0.1 [iM, TA + VP l|iM and TA + VP 10 |iM). When the cells 
pretreated with PIN IjiM and 10|iM, the caspaseS expression was decreased to baseline 
levels before 40 minute, while gene caspaseS expression was increased at 10 minute and 
gradually down at 40 minute when the cells were treated with TA alone and TA + VP 
0.1 ^ iM. 
** p<0.05 
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Figure 3.12 
Semi-quantification of PGR band intensity of c-fos normalized with GAPDH at 
different time points when the cells were treated with different treatment strategies 
(TA alone, TA + PIN 0.1 ^ M, TA + PIN l^iM and TA + PIN 10 ^iM). Gene c-fos 
expression in RPE cells was increased at about 10 minutes after treated with TA, and 
quickly reduced to basal level at about 30 minute. The c-fos expression on cells pretreated 
with pinacidil 0.1 |xM did not show any difference from that of treated with TA alone, 
while c-fos expression significantly decreased when the cells were pretreated with 
pinacidil l|iM and lOjiM compared with the cells being pretreated with pinacidil 0.1 |iM 
at 10 and 20 minute. There are no difference of c-fos expression between the cells were 
pretreated with pinacidil IjiM and lOjiM. 
** p<0.05 
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Gene expression of c-jun over time 
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Figure 3.13 
Semi-quantification of PCR band intensity of c-jun normalized with GAPDH at 
different time points when the cells were treated with different treatment strategies 
(TA alone, TA + PIN O.l^iM，TA + PIN l^M and TA + PIN 10 \LM). Gene c-jun 
expression in RPE cells increased at about 20 minutes after treated with TA, and quickly 
reduced to basal level at about 30 minute. The c-jun expression on cells pretreated with 
pinacidil 0.1 jiM and l)iM did not show any difference from the cells treated with TA 
alone, while c-jun expression decreased when the cells were pretreated with pinacidil 
lO^iM. 
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Figure 3.14 
Semi-quantification of PCR band intensity of c-fos normalized with GAPDH at 
different time points when the cells were treated with different treatment strategies 
(TA alone, TA + VP 0.1 |iM, TA + VP l|iM andTA +VP 10 [iM). Gene c-fos expression 
significantly was decreased when the cells were pretreated with VP \\iM and \0\LM 
compared with the cells being pretreated with VP 0.1 jiM and treated with TA alone. The 
peak time expression of c-fos is at 10 minute and rapidly down at 20 minute when the 
cells were treated with TA and VP 0.1 \iM. 
** p<0.05 
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Figure 3.15 
Semi-quantification of PCR band intensity of c-jun normalized with GAPDH at 
different time points when the cells were treated with different treatment strategies 
(TA alone, TA + VP 0.1 |iM, TA+VP 1 [iM and TA + VP 10 ^iM). The c-jun expression on 
cells pretreated with verapamil 0.1| iMand 1 |iM did not show any difference from the 
cells treated with TA alone, while c-jun expression decreased when the cells were 
pretreated with verapamil lOjiM at 10 and 20 minute. 
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Figure 3.16 
Protein expression of c-fos on RPE cells in the presence of different treatment 
strategies (A. Negative control; B. Positive control; C. TA O.lmg/ml; D. TA+PIN O.l^ iM; 
E. TA + PIN l^M; F. TA + PIN lOjiM). When the cells were pretreated with PIN l|iM 
and lOfxM, the intensity of c-fos expression was reduced greatly compared with the cells 




Protein expression of c-fos on RPE ceils in the presence of different treatment 
strategies (A. Negative control; B. Positive control; C. TA O.lmg/ml; D. TA +VP 0.1 ^ iM; 
E. TA + VP l^iM; F. TA + VP 1 0 _ . When the cells were pretreated with VP 10|iM, the 
intensity of c-fos expression was reduced compared with the cells treated with TA alone. 
There are slightly decrease when the cells pretreated with the VP l \ M and lO^iM 





Protein expression of c-jun on RPE cells in the presence of different treatment 
strategies (A. Negative control; B. Positive control; C. TA O.lmg/ml; D. TA+PIN 0.1 |iM; 
E. TA + PIN IpM; F. TA + PIN 1 0 _ . When the cells were pretreated with PIN 10|iM, 
the intensity oi c-jun expression was reduced compared with the cells pretreated with PIN 




Protein expression of c-jun on RPE cells in the presence of different treatment 
strategies (A. Negative control; B. Positive control; C. TA 0. Img/ml; D. TA + VP 0.1 [iM; 
E. TA + VP l^M; F. TA + VP lO^iM). The intensity of c-jun expression seems reduced 
when the cells were pretreated with VP, especially the higher concentration of VP 




CaspaseS expression in the presence of camptothecin (positive control). There is no 
expression in the presence of different concentrations of PIN. 
B B I ^ H I 
Figure 3.21 
Caspase3 expression in the presence of camptothecin (positive control). There is no 
expression in the presence of different concentrations of VP. 
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Parameters I P I N [ P I N I P I N I W 
O . l ^ I M + T A l^M+TA lOnM+TA O.lnM+TA l[iM+TA lOnM+TA 
M T T ++ -H- +++ ++ ++ +++ 
on day 5 
CaspaseS - ++ - jH^ ++ 
c-fos - - ++ 
c-jun - I 一 I + + - I + I + 
Table 3.1 Summaries of the r esults o f M TT a ssay o n D ay 5 and g ene e xpression 
within 40 minutes when the cells were treated with P I N / V P + TA compared with TA 
alone. - means no difference; + means p is around 0.05; ++ means p = 0.05-0.001; +++ 
means p < 0.001 
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caspn. e31 A PDH 11\ alone PI O. I+TA PI I+TA PIN 10+TA 
0' 1. 17 1.06 0.99 1.04 
10' 1.1 9 1.05 0.92 0.98 
20' 1.1 5 0.99 1.00 0.92 
JO' 1.05 1.02 0.90 0.83 
40' 1.09 0.96 0.88 0.82 
50' 1.10 1. 13 0.92 0.95 
60' 1.04 1. 13 0.88 0.86 
90' 1.12 0.95 0.96 0.89 
(osl A P H TA alone PI O. I+TA PfNl +TA PIN I O+TA 
0 1.7 1 1.57 1.43 1.30 
10' 1.69 I . -0 1.25 1.1 4 
20' 1.84 1. -8 1.26 1.17 
. 0' 1.25 1.34 1.09 1.17 
40' 1.J3 1.25 1.03 1.08 
50' 1.2 1 I .J I 1.09 1.04 
60' 1.24 1.23 1.00 0.98 
90' 1.03 1.06 0.96 0.89 
iUIII AP H TA alone PINO. I+TA PfN I+TA PIN I O+TA 
0 1.07 1.17 1.14 0.82 
10' 1.09 1.1 5 1.05 0.78 
20' 1.24 1.13 1.03 0.81 
JO' 1.13 1. 14 0.89 0.83 
40' 1.1 7 1.06 0.92 0.75 
50' 1. 17 1.07 0.87 0.68 
60' 1.00 1.05 0.81 0.65 
90' 1.10 0.92 0.82 0.56 
Table 3.2 
Relative intensity in staining for Caspase3, c-fos and c-jun expression normalized 
with GAPDH over time in the presence of different concentrations of PIN. 
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cav"r7.�.e.?/GAl)DH TA alone VPO.l+TA V P l + T A VPIO+TA 
0 2.02 l.<S7 1.74 1.25 
10. 2.46 2.51 1.78 1.47 
20' 1.90 2.02 1.52 丨.34 
30' 2.07 1.90 1.30 丨.57 
40. 丨.72 1.62 1.17 1.40 
50' 丨.78 1.50 1.66 
60' 1.64 2.13 1.06 丨.38 
90. 1.48 1.79 1.29 丨.27 
fos/GAPDW TA alone VPO.l+TA V P l + T A VPIO+TA 
0 2.89 1.91 2.35 1.52 
10, 3.20 2.82 2.30 1.67 
20. 2.38 2.10 1.93 1.58 
30. 2.21 2.05 1.70 1.76 
40' 丨.89 1.80 1.48 1.52 
50' 1.84 丨力7 1.38 丨.67 
60' 丨.59 丨.81 丨.13 1.42 
90, 1.20 1.52 1.11 1.31 
7/V///GAPDH TA alone VPO.l+TA V P l + T A VPIO+TA 
0 2.03 丨.6丨 丨.81 丨.37 
10' 2.33 2.37 1.97 1.49 
20. 2.01 1.86 丨.74 1.39 
30' 1.75 1.68 1.48 1.60 
40. 丨.56 1.71 丨.28 丨.38 
50' 丨.6丨 1.75 丨.44 丨.62 
60. 丨.43 2.04 丨.25 1.24 
90. 1.29 丨.68 丨.丨4 丨.14 
Table 3.3 
Relative intensity of staining for CaspaseS, c-fos and c-jun expressions normalized 




In this study, expression of apoptosis gene caspaseS was found to be increased and 
the cell viability was reduced when the cells were treated with TA O.lmg/ml. Pretreated 
with K CO, p inacidil and C a^ "^  c hannel b locker, v erapamil c an i ncrease t he v lability of 
cells upon exposure to TA. Stress-related genes, c-fos and c-jun expression decreased on 
the cells pretreated with pinacidil or verapamil compared with the cells being treated with 
TA alone. 
TA has been widely used and evaluated as an anti-inflammatory glucocorticoid for a 
wide range of systemic or ocular diseases (Raynauld et al” 2003; Zemir et al.’ 2002; 
Yoshikawa et al., 1995; Jonas et al.’ 2001，2002). Intravitreal injection crystal suspension 
of TA seems a promising approach to manage ocular posterior segment diseases. This 
study found that TA O.lmg/ml indeed led to cell death, which is in agreement with a 
recent study (Yeung et al, 2003), which also reported TA to be cytotoxic to cultured 
human retinal pigmented epithelium cells. In contrary, one early study demonstrated lack 
of toxicity of intrvitreally administered Img TAin rabbits (Tano et al 1980). Another 
study reported up to 4mg TA could be safely injected in silicone-filled, vitrectomized 
rabbit eyes without any significant retinal toxicity (Kivilcim et al” 2000). Possible 
explanation is that the duration of TA on the eyes in these two studies were more than 
86 
three months, the actual concentration of intravitreal TA may be much lower because of 
the metabolism in the body, which might be contribute to the difference between the 
results obtained from in vivo and in vitro experiments. 
To investigate the mechanism that underlies cell death, the level of proapoptosis 
gene caspaseS was measured because it is on the final stage in the process of apoptosis 
(Tewari et al., 1995; Ferri et al” 2001; Green et al., 1998; Ravagnan et al” 2002). This 
study showed the gene expression of caspaseS increased after TA treatment, which 
indicated that apoptosis is at least partly involved in the related cell death (Thomberry 
and Lazebnik, 1998). After triggered by initiator caspases (such as caspase 9)，caspaseS 
companied with other effector caspases proteolytically cleave a lot of cellular targets (Shi 
et al” 2002). Compelling evidence provide support to TA induced apoptosis. It has been 
reported that TA was one of the most effective inducers of apoptosis (Hofmann et al” 
1998). The TA-induced apoptosis on airway epithelial cells was associated with cleavage 
of nuclear chromatin, mitochondria depolarization, cytochrome C extrusion and 
activation of caspase 9 (Rorscheid et al,, 2001). Although Fas antigen might be partly 
related to apoptotic muscle death in TA-induced myopathy (Lee et al” 2001), the gene 
regulation p athway especially mitochondria mediated p athway p lays a vital role in the 
process of apoptosis (Ueda et al., 2002). 
MAPK is widely accepted as one of important transduction signal pathways to 
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apoptosis for various environmental stress, such as strain, UV light, y-irradiation, DNA 
damage, heat shock, osmotic shock and oxidative stress (Amoczky et al.’ 2002; English et 
al., 1999; Hagemann and Blank, 2001; Robinson and Cobb, 1997; Schaeffer and Weber, 
1999). Aplidin, a new anti-tumoural drug, was found inhibits cell viability. It was also 
found to rapidly and persistently activate the MAPK pathway (Garcia-Femandez et al., 
2002). C-jun and c-fos, as members of the activation protein AP-1 family of transcription 
factors, also have been believed to be a mediator of the early response of cells to external 
stimuli (Angel and Karin, 1991; Karin et al., 1997). 
In this study, the gene expression of c-jun and c-fos increased paralleled with results 
of the immunofluorescence staining after TA treatment. One previous study suggested that 
GR complex formation by itself or with other transcription factor is important for the 
regulation of GR and c-jun genes (Barrett et al” 1996). The same group researchers had 
earlier found a novel mechanism for the coupled regulation of GR and c-jun transcription 
via a direct transcriptional interference with AP-1 activity (Vig et al.，1994). Kong et al 
on 1998 reported that cells exposed to different chemical agents display pro-apoptotic and 
pro-survival JNK activity. Specific agents with higher concentration can lead to apoptosis 
(Kong et al” 1998). Similar evidence was reported by other studies. Under different 
conditions, fibroblasts expressed both pro-apoptotic and pro-survival roles of c-jun in 
knockout mice (Kolbus et al” 2000; Shaulian et al., 2000; Wisdom et al,’ 1999). The 
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linkage of JNK pathway might be related to the mitochondrial death machinery 
(Garcia-Femandez et al” 2002). Detection of over-activation of JNKl and p38 kinases 
in pharmacologically induced RPE cell death suggested that this signal pathway is 
common to RPE cell death induced by various stress stimuli (Hecquet et al” 2003). 
Another recent study indicated that the JNK pathway is a direct activator of mitochondrial 
death machinery from oxidative stress without other cellular components (Aoki et al., 
2002). Since the AP-1 proteins modifications are identical irrespective of the nature of 
stimuli (Gottlicher et al.’ 1997)，it is possible to propose a hypothesis on the mechanism 
by which the chemical agents-induced apoptosis can be shared with TA. 
In the present study, TA was found to induce apoptosis on RPE cells; JNK signal 
pathway seems to be involved in the process of TA-induced apoptosis. Our results help to 
understand the mechanism of alleviation of the cytotoxic effects of TA. This study 
novelly used the K+ channel opener and Ca^ "^  channel blocker to investigate whether 
concomitant use of ion channel modulator and TA can alleviate the TA induced cytotoxic 
effect. 
In recent years, pinacidil has been found to contribute to cytoprotection in many 
conditions. The mechanism underlies its cytoprotective effect has been widely 
investigated in many organs, especially the cardiovascular system. Cole & colleagues 
suggested a direct cardioprotective effect is due to the shortening of the action potential 
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duration and subsequent reduction in Ca^^ entry (Cole et al., 1991). Another suggestion is 
that pinacidil protects cardiomyocytes from metabolic inhibition-induced injury by 
cyanide through a delay in the onset of increase in Ca^ "^ , rather than by inhibition of the 
L-type Ca2+ -channels or by alteration of Na+-Ca2+ exchange (Tang et al” 1999). 
Especially, the mitochondria pathway has attracted much more attention since the 
successful purification-reconstitution of mitoKAXp channel in the inner membrane (Paucek 
et al.’ 1992). Compelling evidence has shown that the mitochondria may play an 
important role onKCO-induced cytoprotective effect. Cardioprotective effect might be 
the consequence of opening of mitochondria KATP channels rather than sarcolemmal KATP 
channels (Garlid et al,’ 1997; Liu et al., 1998; Sato et al” 2000). P 1075, an analogue of 
pinacidil, opens mitoKATP channels and protects the ischemic rabbit heart in a 
mitoKATP-dependent manner (Oldenberg et al., 2003). Cardioprotection is due to partial 
mitochondria membrane depolarization and then attenuation of mitochondria Ca 
overload (Murata et al., 2001). The opening of mitoKAXp channels may act early in the 
apoptotic cascade by inhibiting cytochrom C release and mitochondria membrane 
depolarization (Akao et al” 2001). MitoKATP channels openers inhibited cerebella granule 
neurons from oxidative stress induced-apoptosis by preserving mitochondrial inner 
membrane potential (Teshima et al., 2003). This study has shown pinacidil also protected 
RPE cells from TA induced-apoptosis. The caspase-3 activation was attenuated when the 
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cells were pretreated with pinacidil or verapamil, which is similar to previous studies. 
Akao et al. reported the cells exposed to 200}iM H2O2 exhibited apoptosis; pretreatment 
with diazoxide (mitochondria spcific K+ channel opener) attenuated the caspase-3 
activation b y about 5 0% (Akao et a /.，2 001). The molecular mechanism underlies this 
warrant further investigation. In this study, MAPK was employed as an index to explore 
the relationship between KCO and TA induced-apoptosis. Gene expressions of c-jun and 
c-fos decreased when the cells were b eing pretreated with higher concentrations (1 |iM 
and 10|iM) of pinacidil. The product of c-jun and c-fos proteins was parallel to those of 
gene expression. On the other hand, protein expression of caspaseS could not be found by 
immunofluorescence when the cells pretreated with pinacidil or verapamil in this study. 
This may suggested the pattern of protein expression of caspaseS is different from those 
of c-jun and c-fos. Different passages of RPE cells may also exaggerate the different 
expression. 
Combined the above information, it is possible to imagine the following picture: TA 
acted as an extracellular stressor when it was used to treat the RPE cells, it elicited the 
activation of PKC and M APK cascade; then the signal was transduced to target gene, 
which regulate the protein expression of c-jun and c-fos, mitochondria membrane 
depolarization and permeability of mitochondria membrane altered, followed by 
cytochrom C releasing, finally triggers the caspases cascade (Figure 4.1). One related 
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study suggested the preconditioning by diazoxide might also activate the protein kinase C 
and MAP kinases (Baines et al., 1999; Takashi et al.’ 1999). This study suggested 
blocking of any levels of the whole process could result in inhibiting apoptosis. The 
altered gene expression of c-jun, c-fos after pretreatment with pinacidil indicates an 
earlier level of regulation before mitochondrial activity, or a signal amplification loop 
may be existed between transcription factor and mitochondria. The results agreed with 
other studies, which demonstrated the regulation might be at the level of cellular DNA 
synthesis (Malhi et al.，2000; Woodfork et al.，1995). In addiction, multi-pathway may be 
involved in pinacidil-induced cytoprotective effect on RPE cells at the same time. There 
can be at least two possibilities: 1) Cytoplastic membrane in cardiac muscle was 
originally thought to involved in ischemic preconditioning and ischemic protection by 
KCO (Grover et al” 1989; Nichols et al.’ 1991); 2) mitochondria membrane can alter the 
mitochondria inner membrane potentiJ, inhibit the membrane permeability, decrease the 
release of the cytochrome C and other death-promoting proteins (Newmeyer and 
Ferguson-Miller, 2003), and 3) even ER, which is another intracellular Ca^ "" store (Ferri 
and Kroemer, 2001; Kaufman et al., 2002). 
In this study it is interesting to find that the higher concentrations (1 and lOjiM) of 
pinacidil display obvious cytoprotective effect, thus indicating the cytoprotective activity 
not to be dose-dependent, which was confirmed by the gene expression and specific 
9 2 
antibodies expression. 
Verapamil, as one of first-generation Ca^^ channel blockers, was clinically used for 
cardiovascular system disorders, especially arrythmia (Braunwald et al” 1982). It has also 
been shown cytoprotective effect on various tissues. The mechanism behind its 
cytoprotective effect is controversial. Verapamil prevent atractyloside-induced toxicity in 
rat renal and liver slices by reduction of lactate dehydrogenase leakage, decreased 
induction o f 1 ipid p eroxidation, p artial p rotection a gainst i nhibition of g luconeogenesis 
and abolition of ATP depletion (Obatomi et al” 2001). Verapamil contributed its 
cytoprotective and anti-inflammatory effects to selectively modulate the production of 
some pro- and anti-inflammatory mediators in endotoxemia (Szabo et al., 1997). The 
nonreceptor-mediated antioxidant activity of verapamil may contribute to cytoprotective 
mechanisms of action in cardiovascular diseases (Mason et al., 1999). Intraportal 
verapamil administration reduces the ischemia-reperfUsion injury caused by free oxygen 
radicals (Erdogan et al., 2001). The results from Koo et al. demonstrated that verapamil 
exerts a protective effect against Ca^'^-induced mitochondria damage which may be 
mediated in part by its effect to the suppression of mitochondria Ca^ "^  uptake and 
mitochondria phospholipase activity (Koo et al” 1995). 
In the present study, verapamil (10|iM) was found to protect the cell from 
TA-induced cytotoxicity. One related study reported that verapamil pretected 
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simvastatin-induced apoptosis by attenuating cytosolic free Ca^^ concentration, inhibiting 
calpain activity and blocking caspase-3 activation (Cheng et al” 2003). Another recent 
study found that verapamil at lOjiM is sufficient to induce cell apoptosis, but subsequent 
exposure to 50|iM improved cell survival (Karwatsky et al., 2003). This finding might 
partially explain that verapamil acted in non-dose-dependent manner on RPE cells in 
present study. Gene expression of c-jun and c-fos was downregulated when the cells were 
pretreated with verapamil. The results of immunofluorescence staining were parallel to 
that of gene expression, which is similar to pinacidil treatment strategies. It is possible to 
imagine that verapamil blocked the Ca^^ channels that led to a reduction of cytosolic Ca^ "^  
concentration, followed by intracellular Ca^ "^  store depletion through direct contact with 
cell membrane or unknown soluble mediator (Favre et al” 1996)，the c-jun, c-fos 
expression were activated by direct or cross-talk way. The mitochondria membrane were 
stablized, d ecreased c ytochrome C release, finally, attenuated the activation of caspase 
cascades. The other possibility should be considered including anti-oxidant activity of 
verapamil as described above, which inhibited lipid peroxidation in cellular membrane as 
a result of modulating physicochemical properties of membrane lipid bilayer, regardless 
of calcium channel inhibition (Mason et al, 1999). Hence, pretreatment with verapamil 
on RPE cells might reduce the membrane's affinity to TA. 
It is noteworthy that pinacidil and verapamil display cytoprotective effect when RPE 
9 4 
cells were pretreated with them for about 30 minutes. This finding is consistent with other 
studies. It has been reported that pretreatment with verapamil for 30 or 60 minutes was 
essential for cytoprotective effect on atractyloside-induced toxicity (Obatomi et al” 2001). 
So ion channel modulator may be prophylactic rather than therapeutic to extracellular 
toxic agents. 
The merit of this study is that it is the first time investigation of ion channel 
modulators on TA treated RPE cells, the results were interesting and useful for future 
investigation, and it carries significant clinical implication. However, the expressed 
proteins have notquantified. TUNNEL assay or real time PCR couldbeperformed to 
consolidate the conclusion. However, we have strong MTT evidence and RT-PCR have 
shown statistically significant difference, the results could still support the hypothesis. 
In conclusion, this study demonstrates that (1) potassium channel opener pinacidil 
and calcium channel blocker verapamil exert cytoprotective effect on RPE cells induced 
by TA. 2) The mechanisms of cytotoxicity involved appear to be complicated and include 
alteration in expression of apoptotic gene caspase-3 and early-response gene c-jun, c-fos. 
(3) Further studies using more specific agents such as diaxozide target mitochondria KATP 
channel, the role of ca^ "*" in the process of cytoprotective activity of ion channel 
modulators by showing ca^ "^  image, using other kinase such as protein kinase C as index 
to further explore the mechanism. (4) Other cells should be investigated such as lens 
95 
epithelial cells or trabecular meshwork cells since TA may have other side effects of 
cataract and elevation of lOP. (5) Clinically, our results provide a new direction on the use 
of channel modulators to attenuate drug toxicity, where wile animal models should b e 
developed to further confirm the effect in vivo. 
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Pathway of TA induced apoptosis and protective effect exerted by PIN/VP. Exposing 
to TA induces RPE stress, this extracellular stimuli activated MAPK pathway, in which 
c-jun and c-fos, as a transcription factor, were activated, then triggered the caspase 
cascade, in the final stage, effector caspaseS was activated and cell apoptosis (black line). 
Pretreatment with PIN/VP decrease activation of MAPK pathway (green line) hence 




Ahnfelt-Ronne I.: Pinacidil: history, basic pharmacology, and therapeutic implications. J. 
Cardiovasc. Pharmacol. 12 Suppl. 2: S1-S4, 1988. 
Akao M.; Ohler A.; O'Rourke B.; Marban E.: Mitochondrial ATP-sensitive potassium 
channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circ. Res. 88: 
1267-1275，2001. 
Almeida A.; Bunnachak D.; Bumier M.; Wetzels J. R; Burke T. J.; Schrier R. W.: 
Time-dependent protective effects of calcium channel blockers on anoxia- and 
hypoxia-induced proximal tubule injury. J. Pharmacol. Exp. Ther. 260 (2): 526-532,1992. 
Alnemri E. S.; Livingston D. J.; Nichoison D. W.; Salvesen G; Thomberry N. A.; Wong 
W. W. and Yuan J.: Human ICE/CED-3 protease nomenclature. Cell 87:171, 1996. 
Amsterdam A.; Tajima K.; Sasson R.: Cell-specific regulation of apoptosis by 
glucocorticoids: implication to their anti-inflammatory action. Biochem. Pharmacol. 64: 
843-850,2002. 
Andersson K. E.: Clinical pharmacology of potassium channel openers. Pharmacol. 
Toxicol 70(4): 244-254, 1992. 
Angel P. and Karin M.: The role ofjun, fos and the AP-1 complex in cell proliferation and 
transformation. Biochim. Biophys. Acta. 1072: 129-157, 1991. 
Aoki H.; Kang P. M.; Hampe J.; Yoshimura K.; Noma T.; Matsuzaki M. and Izumo S.: 
Direct activation of mitochondrial apoptosis machinery by c-jun N-terminal kinase in 
adult cardiac myocytes. J. Biol. Chem. 277: 10244-10250, 2002. 
Arena J. P. and Kass R. S.: Enhancement of potassium-sensitive current in heart cells by 
pinacidil: evidence of modulation of the ATP-sensitive potassium channel. Circ. Res. 65: 
436-445, 1989. 
Arends M. J.; Morris R. G; Wyllie A. H.: Apoptosis. The role of the endonuclease. Am. J. 
Pathol. 136 (3): 593-608, 1990. 
98 
Amoczky S. P.; Tian T.; Lavagnino M.; Gardner K.; Schuler P.; Morse P.: Activation of 
stress-activated protein kinases (SAPK) in tendon cells following cyclic strain: the effects 
of strain frequency, strain magnitude, and cytosolic calcium. J. Orthop. Res. 20 (5): 
947-952，2002. 
Baines C. R; Cohen M. V. and Downey J. M.: Signal transduction in ischemic 
preconditioning: the role of kinases and mitochondrial K (ATP) channels. J. Cardiovasc. 
Electrophysiol. 10: 741-754, 1999. 
Barrett T. J.; Vig. E. and Vedeckis W. V.: Coordinate regulation of glucocorticoid receptor 
and c-jun gene expression is cell type-specific and exhibits differential hormonal 
sensitivity for down and up regulation. Biochem. 35: 9746-9753, 1996. 
Beech D. J.; Zhang H.; Nakao K.; Bolton T. B.: K channel activation by nucleotide 
diphosphates and its inhibition by glibenclamide in vascular smooth muscle cells. Br. J. 
Pharmacol. 110 (2): 573-582, 1993. 
Berger W. E.; Kaiser H.; Gawchik S. M.; Tillinghast J.; Woodworth T. H.; Dupclay L.; 
Georges G C.: Triamcinolone acetonide aqueous nasal spray and fluticasone propionate 
are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis. 
Otolaryngol Head Neck Surg. 129(1): 16-23, 2003. 
Binetmy B.; Smeal T. and Karin M.: Ha-Ras augments c-jun activity and stimulates 
phosphorylation of its activation domain. Nature 351: 122-127,1991. 
Boatright K. M.; Renatus M.; Scott R L.; Sperandio S.; Shin H.; Pedersen I. M.; Ricci J. 
E.; Edris W. A.; Sutherlin D. P.; Green D. R.: A unified model for apical caspase 
activation. Mol. Cell 11: 529-541, 2003. 
Bond A.; Grillner R; Mercuri N. B.; Bemardi G: L-type calcium channels mediate a slow 
excitatory synaptic transmission in rat midbrain dopaminergic neurons. J. Neurosci. 18 
(17): 6693-6703, 1998. 
Borle A. B.: Control, modulation, and regulation of cell calcium. Rev. Physiol. Biochem. 
Pharmacol. 90: 13-153, 1981. 
Brancaccio R. R.; Zappi E. G: Delayed type hypersensitivity to intralesional 
triamcinolone acetonide. Cutis. 65(1): 31-33, 2000. 
99 
Braunwald E.: Machanism of action of calcium channel-blocking agents. N. Engl. J. Med. 
307:1618-1627, 1982. 
Budihardjo I.; Oliver H.; Lutter M.; Luo X. and Wang X.: Biochemical pathways of 
caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 15: 269-290, 1999. 
Bunton T. E.; Plopper C. G: Triamcinolone-induced structural alterations in the 
development of the lung of the fetal rhesus macaque. Am. J. Obstet. Gynecol. 148(2): 
203-215, 1984. 
Bychkov R.; Gollasch M.; Ried C.; Luft F. C.; Haller H.: Effects of pinacidil on K+ 
channels in human coronary artery vascular smooth muscle cells. Am. J. Physiol. 273(1 Pt 
1):C161-C171, 1997. 
Cao J. ； Zhang H. and LiuN.: Themodulation ofcellproliferationinducedby growth 
factors in human retinal pigment epithelial cells. Zhonghua Yan Ke Za Zhi 33 (5): 
360-362，1997. 
Carlsen J. E.; Karkel T.; Hilden T.; Tango M.; Trap-Jensen J.: Immediate central and 
peripheral haemodynamic effects of a new vasodilating agent pinacidil (PI 134) in 
hypertensive man. Clin. Physiol. 1(4): 375-384, 1981. 
Challa J. K.; Gillies M. C.; Penfold P. L.; Gyory J. R; Hunyor A. B.; Billson F. A.: 
Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust. 
N. Z. J. Ophthalmol. 26: 277-281, 1998. 
Chandler D. B.; Hida T.; Sheta S.; Proia A. D.; Machemer R.: Improvement in efficacy of 
corticosteroid therapy in an animal model of proliferative vitreoretinopathy by 
pretreatment. Graefes Arch. Clin. Exp. Ophthal. 225(4): 259-265, 1987. 
Chandler D. B.; Rozakis G; de juan E. J. and Machemer R.: The effect of triamcinolone 
acetonide on a refined experimental model of proliferative vitreoretinopathy. Am. 
J.Ophthalmol. 99: 686-690,1985. 
Cheng G; Shan J.; Xu G; Huang J.; Ma J.; Ying S.; Zhu L.: Apoptosis induced by 
simvastatin in rat vascular smooth muscle cell through Ca^^-calpain and caspase-3 
dependent pathway. Pharmacol. Res. 48 (6): 571-578, 2003. 
100 
Christen W. G: Antioxidant vitamins and age-related eye disease. Proc. Assoc. Am. 
Physicians 111: 16-21, 1999. 
Cidlowski J. A.; King K. L.; Evans-Storms R. B.; Montague J. W.; Bortner C. D.; Hughes 
Jr. FM.: The biochemistry and molecular biology of glucocorticoid-induced apoptosis in 
the immunosystem. Recent Prog. Horm. Res. 51: 457-490，1996. 
Ciulla T. A.; Criswell M. H.; Danis R. P.; Hill P. E.: Intravitreal triamcinolone acetonide 
inhibits choroidal neovascularisation in a laser-treated rat model. Arch. Ophthal. 119(3): 
399-404，2000. 
Cohen J. J.; Duke R. C.: Glucocorticoid activation of a calcium-dependent endonuclease 
in thymocyte nuclei leads to cell death. J. Immunol. 132: 38-42,1984. 
Cole W. C.; McPherson C. D.; Sontag D.: ATP-regulated K+ channels protect the 
myocardium against ischemia/reperfusion damage. Circ. Res. 69 (3): 571-581, 1991. 
Cook N. S.; Quast U.; Hof R. P.; Baumlin Y.; Pally C.: Similarities in the mechanism of 
action of two new vasodilator drugs: pinacidil and BRL34915. J. Cardiovasc. Pharmacol. 
11(1): 90-99，1988. 
Cory S. and Adam J. M.: The Bcl2 family: Regulators of the cellular life-or-death swith. 
Nat. Rev. Cancer 2: 647-656, 2002. 
Cory S.; Huang D. C. S. and Adams J. M.: The Bcl-2 Family: Roles in cell survival and 
oncogenesis. Oncogene 22 (53): 8590-8607, 2003. 
Courchesne W. E.; Kunisawa R. and Thomer J.: A putative protein kinase overcomes 
pheromone-induced arrest of cell cycling in S. cerevisiae. Cell 58:1107-1119,1989. 
Cowan K. J. and Storey K. B.: Mitogen-activated protein kinases: new signaling 
pathways functioning in cellular responses to environmental stress. J. Exp. Bio. 206: 
1107-1115，2003. 
Criddle D. N.; Jazbik W.; Scares de Moura R.: Differential vasorelaxant effects of 
levcromakalim and PI060 in the isolated KCl- and RbCl-precontracted human saphenous 
vein: possible involvement of intracellular Ca2+ stores. Eur. J. Pharm. 286: 123-130， 
1995. 
101 
Cui Y.; Giblin J. P.; Clapp L. H.; Tinker A.: A mechanism for ATP-sensitive potassium 
channel diversity: functional coassembly of two pore-forming subunits. Proc. Natl. Acad. 
Sci. U S A. 98 (2): 729-734, 2001. 
Danis R. P.； Bingaman D. P.; Yang Y.; Ladd B.: Inhibition of preretinal and optic nerve 
haead neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthal. 1 03: 
2099-2104, 1996. 
Danis R. P.; Ciulla T. A.; Pratt L. M.; Anliker W.: Intravitreal triamcinolone acetonide in 
exudative age-related macular degeneration. Retina. 20(3): 244-250, 2000. 
Darius M. M.; Careen Y. L.; Daniel B. R.; Peter K. K.: Retinal and choroidal vascular 
occlusion after posterior sub-tenon triamcinolone injection. Am. J. Ophthal. 134: 132-134, 
2002. 
Denhardt D. T.: Signal-transducing protein phosphorylation cascades mediated by 
Ras/Rho proteins in the mammalian cell: the potential for multiplex signaling. Biochem. J. 
318: 729-747, 1996. 
Denizot R; Lang R.: Rapid colorimetric assay for cell growth and survival. Modifications 
to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. 
Methods. 89 (2): 271-277, 1986. 
Doggrell S. A.; Bishop B. E.; Bamett C. W.: The effects of racemic, (+)- and (-) -pinacidil 
on the membrane potential of the rat aorta. J. Pharm. Pharmacol. 47(4): 307-309,1995. 
Domoki R; Perciaccante J. V.; Veltkamp R.; Bari R and Busija D. W.: Mitochondrial 
potassium channel opener diazoxide preserves neuronal-vascular function after cerebral 
ischemia in newborn pigs. Stroke 30: 2713-2718，1999. 
Dorschied D. R.; Wojcik K. R.; Sun S.; Marroquin B. and White S. R.: Apoptosis of 
airway e pithelial cells i nduced b y e orticosteroids. Am. J. R espir. C irt. C are M ed. 1 64: 
1939-1947，2001. 
Doyle J. W.; Dowgiert R. K.; Buzney S. M.: Retinoic acid metabolism in cultured retinal 
pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 36 (3): 708-717，1995. 
Eamshaw W. C.; Martins L. M. and Kaufmann S. H.: Mammalian caspases: structure, 
102 
activation, substrates, and functions during apoptosis. Annu. Rev. Biochem. 68: 383-424, 
1999. 
Elion E. A.; Grisafi P. L. and Fink G R.: FUSS encodes a cdc2+/CDC28-related kinase 
required for the transition from mitosis into conjugation. Cell 60: 649-664, 1990. 
Ellis S. B.; Williams M. E.; Ways N. R.; Brenner R.; Sharp A. H.; Leung A. T.; Campbell 
K. P.; Mckenna E.; Koch W. J.; Hui A. et al.: Sequence and expression of mRNAs 
encoding the alpha 1 and alpha 2 subunits of a DHP-sensitive calcium channel. Science 
241 (4873): 1661-1664, 1988. 
Enari M.; Sakahira H.; Yokoyama H.; Okawa K.; Iwamatsu A. and Nagata S.: A 
caspase-activated Dnase that degrades DNA during apoptosis, and its inhibitor ICAD. 
Nature 391: 43-50, 1998. 
English J.; Pearson G; Wilsbacher J.; Swantek J.; Karandikar M.; Xu S.; Cobb M.: New 
insights into the control of MAP kinase pathways. Exp. Cel. Res. 253: 255-270, 1999. 
Erdogan O.; Yildiz S.; Basaran A.; Demirbas A.; Yesilkaya A.: Effect of intraportal 
verapamil infusion on hepatic ischemia-reperfusion injury. Pol. J. Pharmacol. 53 (2): 
137-141,2001. 
Faivre J. F. and Findlay I.: Effects of tolbutamide, glibenclamide and diazoxide upon 
action potentials recorded from rat ventricular muscle. Biochim. Biophys. Acta. 984: 1-5, 
1989. 
Fans M.; Kokot N.; Latinis K.; Kasibhatla S.; Green D. R.; Koretzky G. A. and Nel. A.: 
The c-jun N-terminal kinase cascade plays a role in stress-induced apoptosis in jurkat 
cells by up-regulating Fas ligand expression. J. Immunol. 160 (1): 134-144,1998. 
Favre C. J.; Niisse O.; Lew D. P. and Krause K. H.: Store-operated Ca2+ influx: what is 
the message from the stores to the membrane? J. Lab. Clin. Med. 128: 19-26，1996. 
Ferri K. F. and Kroemer G: Organelle-specific initiation of cell death pathways. Nat. Cell. 
BioL3:E255-E263,2001. 
Fesik S. W. and Shi Y.: Controlling caspases. Science 294: 1477-1478, 2001. 
103 
Frambach D. A.; Fain G L.; Farber D. B. and Bok D.: Beta adrenergic receptors on 
cultured human retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 31 (9): 
1767-1772’ 1990. 
Friedel H. A.; Brogden R. N.: Pinacidil: A review of its pharmacodynamic and 
pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. 
Drugs. 39(6): 929-967, 1990. 
Fujita A. and Kurachi Y.: Molecular aspects of ATP-sensitive K+ channels in the 
cardiovascular system and K+ channel openers. Pharmacol. Ther. 85: 39-53, 2000. 
Fukuda K. Kojiro M.; Chiu J. R: Demonstration of extensive chromatin cleavage in 
transplanted Morris hepatoma 7777 tissue: apoptosis or necrosis? Am. J. Pathol. 142: 
935-946, 1993. 
Garcia-Femandez L. R; Losada A.; Alcaide V.; Alvarez A. M.; Cuadrado A.; Gonzalez L.; 
Nakayama K.; Nakayama K. L; Femandez-Sousa J. M.; Mimoz A.; Sanchez-Puelles J. M.: 
Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK 
and p38 activation and protein kinase C delta. Oncogene 21 (49): 7533-7544, 2002. 
Garlid K. D.; Paucek P.; Yarov-Yarovoy V.; Murray H. N.; Darbenzio R. B.; D'Alonzo A. 
J. et al.: Cardioprotective effect of diazoxide and its interaction with mitochondrial 
ATP-sensitive K+ channels: possible mechanism of cardioprotection. Circ. Res. 81: 
1071-1082, 1997. 
Garlid K. D. and Paucek P.: Mitochondrial potassium transport: the K+ cycle. Biochim. 
Biophysica. Acta. 1606: 23-41，2003. 
Ghosh A.; Greeberg M. E.: Calcium signaling in neurons: molecular mechanisms and 
cellular consequences. Science 268 (5208): 239-247，1995. 
Gottlicher M.; Ramsdorf H. J.; Herrlich P.: The AP-1 family of transcription factors: 
multi-level control of activity. In: Papavassiliou A. G editor. Transcription factors in 
eukaryotes. Heidelberg: Springer-Verlag. 67-93,1997. 
Graham S. H. and Chen J.: Programmed cell death in cerebral ischemia. J. Cereb. Blood 
Flow Metab. 21: 99-109，2001. 
104 
Green D. R.; Reed J. C.: Mitochondria and apoptosis. Science 281: 1309-1312，1998. 
Gross A.; McDonnell J. M. and Korsmeyer S. J.: Bcl-2 family members and the 
mitochondria in apoptosis. Genes & Dev. 13: 1899-1911, 1999. 
Grover G J.; McCullough J. R.; Henry D. E.; Conder M. L.; Slerph P. G: Anti-ischemic 
effects of the potassium channel activators pinacidil and cromakalim and the reversal of 
these effects with the potassium channel blocker glyburide. J. Pharmacol. Exp. Ther. 
251(1): 98-104, 1989. 
Grover G J.; Garlid K. D.: ATP-Sensitive potassium channels: a review of their 
cardioprotective pharmacology. J. Mol. Cell Cardiol. 32(4): 677-695, 2000. 
Hagemann C. and Blank J. L.: The ups and downs of MEK kinase interactions. Cell 
Signal 13(12): 863-875,2001. 
Hagemann C.; Blank J. L.: The ups and downs of MEK kinase interactions. Cell Signal. 
13 (12): 863-875，2001. 
Hagiwara S.; Ozawa S.; Sand O.: Voltage clamp analysis of two inward current 
mechanisms in the egg cell membrane of a starfish. J. Gen. Physiol. 65: 617-644，1975. 
Haraguchi M.; Torii S.; Matsuzawa S.; Xie Z.; Kitada S.; Krajewski S.; Yoshida H.; Mak 
T. W. and Reed J. C.:Apoptotic protease activating factor 1 (Apaf-1 )-independent cell 
death suppression by Bcl-2. J. Exp. Med. 191: 1709-1720，2000. 
Hassan A. H.; Von-Rosenstiel P.; Patchev V. K.; Holsboer R; Almeida O. R: Exacerbation 
of apoptosis in the dentate gyrus of the aged rat by dexamethasone and the protective role 
of corticosterone. Exp. Neurol. 140: 43-52, 1996. 
Haynes R. C.: Jr. in: Goodman and Oilman's The pharmacological basis of therapeutics, 
8出 Edn.( Oilman A. G; Roll T. W.; Nies A. S. and Taylor P.)： pp. 1452-1457,1990 
Hecquet C.; Lefevre G; Valtink M.; Engelmann K. and Maccarelli R: Activation and role 
of MAP kinase-dependent pathways in retinal pigment epithelium cells: JNKl, P38 
kinase, and cell death. Invest. Ophthalol. Vis. Sci. 44: 1320-1329，2003. 
Hermsmeyer K.: Ion channel effects of pinacidil in vascular muscle. Drugs. 36 Suppl. 7: 
29-32, 1988. 
105 
Hess J.; Porte D.; Munz C.; Angel P.: AP-1 and Cbfa/runt physically interact and regulate 
parathyroid hormone-dependent MMP13 expression in osteoblasts through a new 
osteoblast-specific element 2/AP-1 composite element. J. Biol. Chem. 276 (23): 
20029-20038, 2001. 
Hida T.; Chandler D.; Arena J. E. and Machemer R.: Experimental and clinical 
observations of the intraocular toxicity of commercial corticosteroid preparations. Am. J. 
Ophthalmol. 101: 190-195,1986. 
Hisahara S.; Yuan J.; Momoi T.; Okano H. and Miura M.: Caspase-11 mediates 
oligodendrocyte cell death and pathogenesis of autoimmune-mediated demyelination. J. 
Exp. Med. 193: 111-122, 2001. 
Ho K.; Nichols C . G.; Lederer W. J. ； Lytton J. ； Vassilev P. M.; KanazirskaM. V. and 
Hebert S. C.: Cloning and expression of an inwardly rectifying ATP-regulated potassium 
channel. Nature 362: 31-38，1993. 
Hochhaus G; Gonzalez M. A.; Dockhom R. J.; Shilstone J.; Karafilidis J.: A new 
solution-based intranasal triamcinolone acetonide formulation in patients with perennial 
allergic rhinitis: how does the pharmacokinetic/ pharmacodynamic profile for Cortisol 
suppression compare with an aqueous suspension-based formulation? J. Clin. Pharmacol. 
42(6): 662-669，2002. 
Howflich K. P. and Woodgett J. R.: Signal transduction and gene expression in the 
regulation of natural freezing survival. In Cell and Molecular Responses to Stress. 2: 
175-193,2001. 
Hofmann T. G; Hehner S. P.; Bacher S.; Droge W.; Schmitz M. L.: Various 
glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress 
NF-Kb-dependent transcription. Fed. Eur. Biochem. Soc. 441: 441-446，1998. 
Hong K.W.; Park M.G; Shin Y. M.; Rhim B. Y.; Ko K. H.: Effect of ouabain on relaxation 
induced by cromakalim in human and canine mesenteric arteries. Eur. J. Pharmacol. 
231(1): 1-6, 1993. 
Hu Y.; Benedict M.A.; Ding L.; Nunez G: Role of cytochrome C and dATP/ATP 
hydrolysis in Apaf-1 •mediated caspase-9 activation and apoptosis. EMBO J. 18: 
106 
3586-3595, 1999. 
Huettenbrenner S.; Maier S.; Leisser C.; Polgar D.; Strasser S. Grusch M.; Krupitza G: 
The evolution of cell death programs as prerequisites of multicellularity. Mutat. Res. 
543(3): 235-249, 2003. 
Hughes B. A.; Takahira M.: Inwardly rectifying K+ currents in isolated human retinal 
pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 37: 1125-1139, 1996. 
Inagaki N.; Gonoi T.; Clement J. P.; Namba N.; Inazawa J.; Gonzalez G; Aguilar-Bryan 
L.; Seino S. and Bryan J.: Reconstitution of DCATP: an inward retifier subunit plus the 
sulfonylurea receptor. Science 270: 1166-1170,1995a. 
Inagaki N.; Tsuura Y.; Namba N.; Masuda K.; Gonoi T.; Horie M.; Seino Y.; Mizuta M. 
and Seino S.: Cloning and functional characterization of a novel ATP-sensitive potassium 
channel ubiquitously expressed in rat tissues, including pancreatic islets, pituitary, skeletal 
muscle and heart. J. Biol. Chem. 270: 5691-5694, 1995b. 
Irving E. A. and Bamford M.: Role of mitogen- and stress-activated kinases in ischemic 
injury. J. Cereb. Blood Flow Metab. 22: 631-647，2002. 
Ishibashi T.; Koichiro M.; Sorgente N.; Patterson R. and Ryan S. J.: Effects of intravitreal 
administration of steroids on experimental subretinal neovascularization in the subhuman 
primate. Arch. Ophthalmol. 103: 708-711, 1985. 
Ishibashi T.; Sorgente N.; Patterson R. and Ryan S. J.: Pathogenesis of drusen in the 
primate. Invest. Ophthalmol. Vis. Sci. 27: 184-193，1986. 
Isomoto S.; Kondo C.; Takahashi N.; Matsumoto S.; Yamada M.; Takumi T.; Horio Y. and 
Kurachi Y.: A novel ubiquitously distributed isoform of GIRK2 (GIRK2B) enhances 
GIRKl expression of the G-protein-gated K+ current in Xenopus oocytes. Biochem. 
Biophys. Res. Commun. 218: 286-291，1996a. 
Itoh T.; Seki N.; Suzuki S.; Ito S.; Kajikuri J.; Kuriyama H.: Membrane hyperpolarization 
inhibits agonist-induced synthesis of inositol 1，4，5- trisphosphate in rabbit mesenteric 
artery. J. Physiol. 451: 307-328，1992. 
Iwamoto T.; Nishimura N.; Morita T.; Sukamoto T.: Defferential vasorelaxant effects of 
107 
K(+)- channel blockers on canine isolated arteries. J. Pharm. Pharmacol. 45(4): 292-297, 
1993. 
Jay S. D.; Ellis S. B.; McCue A. F.; Williams M. E.; Vedvick T. S.; Harpold M. M.; 
Campbell K. P.: Primary structure of the gamma subunit of the DHP-sensitive calcium 
channel from skeletal muscle. Science 248 (4954): 490-492, 1990. 
Jonas J. B.; Hayler J. K.; Panda-Jonas S. Intravitreal injection of crystalline cortisone as 
adjunctive treatment of proliferative vitreoretinopathy. Br. J. Ophthal. 84(9): 1064-1067, 
2000. 
Jonas J. B.; Hayler J. K.; Sofker A.; Panda-Jonas S. Regression of neovascular iris vessels 
by intravitreal injection of crystalline cortisone. J. Glaucoma. 10(4): 284-287, 2001. 
Jonas J. B.; Sofker A.: Intraocular injection of crystalline cortisone as adjunctive 
treatment of diabetic macular edema. Am. J. Ophthal. 132: 425-427, 2001. 
Jonas J. B.; Hayler J. K.; Sofker A.; Panda-Jonas S.: Intravitreal injection of crystalline 
cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am. J. Ophthalmol. 
131: 468-471，2001. 
Jonas J. B.; Kreissig L; Degenring R. Intravitreal triamcinolone acetonide as treatment 
of macular edema in central retinal vein occlusion. Graefes. Arch. Clin. Exp. Ophthal. 
240(9); 782-783’ 2002. 
Jonas J. B.; Kreissig L; Sofker A.; Degenring R. F. Intravitreal injection of 
triamcinolone for diffuse diabetic macular edema. Arch. Ophthal. 121(1): 57-61, 2003. 
Jovanovic A.; Jovanovic S.; Lorenz E.; Terzic A.: Recombinant cardiac ATP-sensitive K+ 
channel subunits confer resistance to chemical hypoxia-reoxygenation injury. Circulation. 
98(15): 1548-1555, 1998. 
Jovanovic N.; Jovanovic S.; Jovanovic A.; Terzic A.: Gene delivery of Kir6.2/SUR2A in 
conjunction with pinacidil handles intracellular Ca^^ homeostasis under metabolic stress. 
FASEB J. 13(8): 923-929, 1999. 
Joyce D. A.; Steer J. H. and Abraham L. J.: Glucocorticoid modulation of human 
monocyte/macrophage function: control of TNF-alpha secretion. Inflamm. Res. 46: 
108 
447-451，1997b. 
Karin M.: The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. 
Chem. 270: 16483-16486，1995. 
Karin M.; Liu Z. G and Zandi E.: AP-1 function and regulation. Curr. Opin. Cell Biol. 9: 
240-246，1997. 
Karwatsky J.; Lincoln M. C.; Georges E.: A mechanism for P-glycoprotein-mediated 
apoptosis as revealed by verapamil hypersensitivity. Biochem. 42: 12163-12173, 2003. 
Kaufman R. J.: Orchestrating the unfolded protein response in health and disease. J. Clin. 
Invest. 110: 1389-1398，2002. 
Kawashima S.; Liang C. S.: Systemic and coronary hemodynamic effects of pinacidil in 
awake normotensive and hypertensive dogs. Hypertension. 7(4): 525-532, 1985. 
Kawashima S.; Liang C. S.: Systemic and coronary hemodynamic effects of pinacidil, a 
new antihypertensive agent, in awake dogs: comparison with hydralazine. J. Pharmacol. 
Exp. Ther. 232(2): 369-375, 1985. 
Kerr J. R; Wyllie A. H. and Currie A. R.: Apoptosis: a basic biological phenomenon with 
wide-ranging implications in tissue kinetics. Br. J. Cancer 26: 239-257, 1972. 
Kim S. and Iwao H.: Stress and vascular responses: mitogen-activated protein kinases and 
activator protein-1 as promising therapeutic targets of vascular remodeling. J. Pharmacol. 
Sci. 91: 177-181，2003. 
Kivilcim M.; Peyman G. A.; El-Dessouky E. S.; Kazi A. A.; Cheema R.; Hegazy H.: 
Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic. Surg. 
Lasers. 31(6): 474-478，2000. 
Kletsas D.; Basdra E. K. and Papavassiliou A. G: Effect of protein kinase inhibitors on 
the stretch-elicited c-fos and c-jun up-regulation in human PDL osteoblast-like cells. J. 
Cell. Physiol. 190: 313-321，2002. 
Kolbus A.; Heir I.; Schreiber M.; Debatin K. M.; Wagner E. R and Angel P.: 
c-7WA2-dependent CD95-L expression is a rate-limiting step in the induction of apoptosis 
by alkylating agents. Mol. Cell Biol. 20 (2): 575-582, 2000. 
109 
Kong A. N.; Yu R.; Lei W.; Mandlekar S.; Tan T. H.; Ucker D. S.: Differential activation 
of MAPK and ICE/Ced-3 protease in chemical-induced apoptosis: the role of oxidative 
stress in the regulation of mitogen-activated protein kinases (MAPKs) leading to gene 
expression and survival or activation of caspases leading to apoptosis. Restor. Neurol. 
Neurosci. 12 (2,3): 63-70，1998. 
Koo W. S.; Gengaro P. E.; Bruke T. J.; Schrier R. W.: Verapamil attenuates 
calcium-induced mitochondrial swelling and respiratory dysfunction. J. Pharmacol. Exp. 
Then 273 (1): 206-212, 1995. 
Kostyuk P. G: Diversity of calcium ion channels in cellular membranes. Neuroscience 28 
(2): 253-261，1989. 
Kribben A.; Wieder E. D.; Wetzels J. R; Yu L.; Gengaro R E.; Burke T. J.; Schrier R. W.: 
Evidence for role of cytosolic free calcium in hypoxia-induced proximal tubule injury. J. 
Clin. Invest. 93 (5): 1922-1929, 1994. 
Kwok W. M.; Kass R. S.: Inhibition of pinacidil induced IK(ATP) in heart by changes in 
extracellular PH. Cardiovasc. Res. 28(6): 836-840,1994. 
Lafranco D. M.; Tran V. T.; Guex-Crosier Y. and Herbert C. O.: Posterior sub-Tenon's 
steroid injections for the treatment of posterior ocular inflammation: indications, efficacy 
and side effects. Graefe's Arch. Clin. Exp. Ophthalmol. 237: 289-295, 1999. 
Lee E.; Joen S. H.; Yi J. Y.; Jin Y. J.; Son Y. S.: Calcipotriol inhibits autocrine 
phosphorylation of EGF receptor in a calcium-dependent manner, a possible mechanism 
for its inhibition of cell proliferation and stimulation of cell differentiation. Biochem. 
Biophys. Res. Commun. 284(2): 419-425，2001. 
Lee M. C.; Lee J. S.; Lee J. M.; Lee J. H. and Kim H. I.: Fas mediates apoptosis in 
steroid-induced myopathy of rats. Neuropathology and Applied Neurobiology 27: 
396-402，2001. 
Lee S. W.; Tsou A. P.; Chan H.; Thomas J.; Petrie K.; Eugui E. M.; Allison A. C.: 
Glucocorticoids selectively inhibit the transcription of the interleukins IB gene and 
decrease the stability of interleukins IB mRNA. Proc. Natl. Acad. Sci. U.S.A. 85: 
1204-1208，1988. 
110 
Leibovitch S. J. and Ross R.: The role of the macrophage in wound repair: a study with 
hydrocortisone and antimacrophage serum. Am. J. Pathol. 78: 71-99，1975. 
Lennon S. V.; Martin S. J.; Cotter T. G: Dose-dependent induction of apoptosis in human 
tumor cell lines by widely diverting stimuli. Cell Prolif. 24: 203-214, 1991. 
Liu D.; Lu C.; Wan R.; Auyeung W. W. and Mattson M. P.: Activation of mitochondrial 
ATP-dependent potassium channels protects neurons against ischemia-induced death by a 
mechanism involving suppression of Bax translation and cytochrome C release. J. 
Cereb.Blood Flow Metab. 22: 431-443，2002. 
Liu X.; Zou H.; Slaughter C. and Wang X.: DFF, a heterodimeric protein that functions 
downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 
89:175-184, 1997. 
Liu X.; Li P.; Widlak P.; Zou H.; Luo X.; Garrard W. T. and Wang X.: The 40-kDa subunit 
of DNA fragmentation factor induces DNA fragmentation and chromatin condensation 
during apoptosis. Proc. Natl. Acad. Sci. USA 95:8461-8466,1998. 
Liu Y.; Ren G; O'Rourke B.; Marban E.; Seharaseyon J.: Pharmacological comparison of 
native mitochondrial K(ATP) channels with molecularly defined surface K(ATP) channels. 
Mol. Pharmacol. 59(2): 225-230, 2001. 
Liu Y.; Sato T.; O'Rourke B.; Marban E.: Mitochondrial ATP-dependent potassium 
channels: novel effectors of cardioprotection? Circ. 97: 2463-2469,1998. 
Lyonel G I.; Esther D. L: Fundamentals of cancer medicine. The Oncologist 4: 332-339, 
1999. 
Machemer R.; Sugita G; Tano Y,: Treatment of intraocular proliferations with intravitreal 
steroids. Trans. Am. Ophthalmol. Soc. 77: 171-180, 1979. 
Mackay D. J. and Hall A.: Rho GTPases. J. Biol. Chem. 273: 20685-20688,1998. 
Malhi H.; Irani A. N.; Rajvanshi P.; Suadicani S. O.; Spray D. C.; McDonald T. V. and 
Gupta S.: KATP channels regulate mitogenically induced proliferation in primary rat 
hepatocytes and human liver cell lines. J. Biol. Chem. 275: 26050-26057, 2000. 
I l l 
Mann C. L.; Cidlowski J. A.: Glucocorticoids regulate plasma membrane potential during 
rat thymocyte apoptosis in vivo and in vitro. Endocrinology 142: 421-429, 2001. 
Marsden V.; O'Connor L.; O'Reilly L. A.; Silke J.; MetcalfD.; Ekert P.; Huang D. C. S.; 
Cecconi R; Kuida K.; Tomaselli K. J. et ah Apoptosis initiated by Bcl-2-regulated 
caspase activation independently of the cytochrome C/Apaf-l/caspase-9 apoptosome. 
Nature 419: 634-637, 2002. 
Martelli AM.; Bortul R.; Fackelmayer FO.; Tazzari PL.; Bareggi R.; Narducci P.; Zweyer 
M.: Biochemical and morphological characterization of the nuclear matrix from apoptotic 
HL-60 cells. J. Cell Biochem. 72(l):35-46, 1999. 
Mason R. P.; Mak T.; Trumbore M. K. and Mason P. E.: Antioxidant properties of calcium 
antagonists related to membrane biophysical interactions. Am. J. Cardiol. 84: 16L-22L, 
1999. 
Martidis A.; Miller D. G; Ciulla T. A.; Danis R. P.; Moorthy R. S.: Corticosteroids as an 
antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J. 
Ocul. Pharm. Then 15: 425-428，1999. I 
Martidis A.; Duker J. S.; Greenberg P. B.; Rogers A. H.; Puliafito C. A.; Reichel E.; 
Baumal C.: Intravitreal triamcinolone for refractory diabetic edema. Ophthal. 109(5): 
920-927，2002. 
McConkey D. J.: The role of calcium in the regulation of apoptosis. Scanning Microsc. 
10(3): 777-793; discussion 793-794, 1996. 
Mckay L.; Cidlowski J. A.: Molecular control of immune/inflammatory responses: 
interaction between nuclear factor-kB and steroid receptor signaling pathways. Endocr. 
Rev. 20: 435-459, 1999. 
McCuen B. W.; Bessler M.; Tano Y.; Chandler D. and Machemer R.: The lack of toxicity 
of intravitreally administered triamcinolone acetonide. Am. J. Ophthalmol. 91: 785-788, 
1981. 
McGhee C. N.; Dean S.; Danesh-Meyer H.: Locally administered ocular corticosteroids: 
benefits and risks. Drug. Saf. 25: 33-55, 2002. 
112 
Meisheri K. D.; Dubray L. A.; Oleynek J. J.: A sensitive in vitro functional assay to detect 
K(+)- channel-dependent vasodilators. J. Pharmacol. Methods. 24(4): 251-261, 1990. 
Michael, L.; Robin, M.: The role of corticosteroids in dermatology. Aust. Prescr. 21:9-10, 
1998. 
Mikkelsen E.; Pedersen O. L.: Comparison of the effects of a new vasodilator pinacidil 
and nifedipine on isolated blood vessels. Acta. Pharmacol. Toxicol. (Cophenh) 51(5): 
407-412，1982. 
Moroi-Fetters S. E.; Barley O.; Hirakata A.; Caron M. G and Jaffe G J.: Binding, 
coupling and mRNAsubtype heterogeneity ofaIpha 1 -adrenergic receptors in cultured 
human RPE. Exp. Eye Res. 60 (5): 527-532, 1995. 
Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays. J. Immunol. Methods. 65 (1-2): 55-63, 1983. 
Munck A.; Crabtree G R.: In: Bowen I. D.; Lockshin R. A. editors: 
Glucocorticoids-induced lymphocyte death. New York: Chapman and Hall. 329-359, 
1981. 
Munz C.; Psichari E.; Mandilis D.; Lavigne A. C.; Spiliotaki M.; Oehler T.; Davidson I.; 
Tora L.; Angel P.; Pintzas A.: TAF7 (TAFII55) plays a role in the transcription activation 
by c-jun. J. Biol. Chem. 278 (24): 21510-21516, 2003. 
Murata M.; Akao M.; O'Rourke B.; Marbki E.: Mitochondrial ATP-sensitive potassium 
channels attenuate matrix Ca^ "^  overload during simulated ischemia and reperfusion: 
possible mechanism of cardioprotection. Circ. Res. 89: 891-898, 2001. 
Murosaki S.; Inagaki-Ohara K.; Kusaka H.; Dceda H.; Yoshikai Y.: Apoptosis of intestinal 
intraepithelial lymphocytes induced by exogenous and endogenous glucocorticoids. 
Microbiol. Immunol. 41: 139-148, 1997. 
Nayler W. G: Second generation of calcium antagonists. Berlin. Springer 1: 1-8，1991. 
Nebreda A. R.; Porras A.: P38 kinase: beyond the stress response. Trends Biochem. 25: 
257-260, 2000. 
113 
New L. and Han J.: The p38 MAP kinase pathway and its biological function. Trends 
Cardiovasc. Med. 8: 220-229,1998. 
Newmeyer D. D. and Ferguson-Miller S.: Mitochondria: releasing power for life and 
unleashing the machineries of death. Cell 112: 481-490, 2003. 
Nichols C. G and Lederer W. J.: Adenosine trisphosphate-sensitive potassium channels in 
the cardiovascular system. Am. J. Physiol. 261: H1675-H1686, 1991. 
Nielsen C. K.; Arrigoni-Martelli E.: Effect o f a new vasodilator, pinacidil (Pll34)，on 
potassium, noradrenaline and serotonin induced contractions in rabbit vascular tissues. 
Acta. Pharmacol. Toxicol. (Copenh). 49(5): 427-431, 1981. 
Noll G; Liischer T. R: Comparative pharmacological properties among calcium channel 
blockers: T-channel versus L-channel blockade. Cardiology 89 (suppl 1): 10-15,1998. 
Nowycky M. C.; Fox A. P.; Tsien R. W.: Three types of neuronal calcium channel with 
different calcium agonist sensitivity. Nature 316 (6027): 440-443，1985. 
Obatomi D. K.; Blackburn R. O.; Bach P. H.: Effects of the calcium channel blocker 
verapamil and sulphydryl reducing agent dithiothreitol on atractyloside toxicity in 
precision-cut rat renal cortical cortical and liver slices. Food and Chem. Toxicity 39: 
1013-1021，2001. 
Oldenberg O.; Yang X. M.; Krieg T.; Garlid K. D.; Cohen M. V.; Grover G J.; Downey J. 
M.: PI075 opens mitochondrial KATP channels and generates reactive oxygen species 
resulting in cardioprotection of rabbit hearts. J. Mol. Cel. Cardiol. 35: 1035-1042，2003. 
Ono K.; Han J.: The P38 kinase signal transduction pathway: activation and function. Cell 
Signal. 12: 1-13，2000. 
Opie L. H.; Biihler F. R.; Fleckenstein A.; Hansson L.; Harrison D. C.; Poole-Wilson P. A.; 
Schwartz A.; Vanhoutte P. M.; Braunwald E.; Nayler W. G et al:. International society 
and federation of cardiology: working group on classification of calcium antagonists for 
cardiovascular disease. Am. J. Cardiol. 60: 630-632,1987. 
O'Rourke R. A.; Walsh R. A.: Experience with calcium antagonist drugs in congestive 
114 
heart failure. Am. J. Cardiol. 59 (3): 64B-69B, 1987. 
Patrick J. L.; Robert W.: Gushing syndrome induced by serial occipital nerve block 
containing corticosteroids. Headache. 41: 902-904，2001. 
Paucek P.; Mironova G; Mahdi R; Beavis A. D.; Woldegiorgis G; Garlid K. D.: 
Reconstitution and partial purification of the glibenclamide-sensitive, ATP-dependent K+ 
channel from rat 1 iver a n d b eef heart mitochondria. J. B iol. Chem. 267: 2 6062-26069, 
1992. 
Paul M. B.; Sophie J. B.; Ravinder J. S.; Weiguo L.; George B. P.; Michael M.: 
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single 
intravitreal injection. Ophthal. 110: 681-686，2003. 
Pearson G; Robinson R; Beer-Gibson T. et al... Mitogen-activated protein (MAP) kinase 
pathways: regulation and physiological functions. Endocr. Rev. 22: 153-183, 2001. 
Penfold P. L.; Wen L.; Madigan M. C.; Gillies M. C.; King N. J. C.; Provis J.M.: 
Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 
(ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. 
Clin. Exp. Immunol. 121: 458-465, 2000. 
Penfold P. L.; Wong J. G; Gyory J.; Billson F. A.: Effects of triamcinolone acetonide on 
microglial morphology and quantitative expression of MHC-II in exudative age-related 
macular degeneration. Clin. Exp. Ophthalmol. 29: 188-192, 2001. 
Poelaert J.; Roosens C.: Peroperative use of dihydropyridine calcium channel blockers. 
Acta. Anaesthesiol. Scand. 44: 528-535, 2000. 
Protti D. A. and Llano I.: Calcium currents and calcium signaling in rod bipolar cells of 
rat retinal slices. J. Neurosci. 18 (10): 3715-3724,1998. 
Prunte C. and Flammer J.: Circulatory disorders of the choroids in patients with central 
serious chorioretinopathy. Klin. Monatsbl. Augenheilkd. 208 (5): 337-339，1996. 
Qing J.; Zhang Y.; Derynck R.: Structural and functional characterization of the 
transforming growth factor-beta -induced SmadS/c-yww transcriptional cooperativity. J. 
Biol. Chem. 275 (49): 38802-38812, 2000. 
115 
Quast U.: Potassium channel openers: pharmacological and clinical aspects. Fimdam. 
Clin. Pharmacol. 6(7): 279-293，1992. 
Ravagnan L.; Roumier T.; Kroemer G: Mitochondria, the killer organelles and their 
weapons. J. Cell Physiol. 192: 131-137，2002. 
Ray A. and Prefontaine K. E.: Proc. Natl. Acad. Sci. U.S.A. 91:752-756,1994. 
Raynauld J. P.; Buckland-Wright C.; Ward R.; Choquette D.; Haraoui B.; Martel-Pelletier 
J.; Uthman I.; Khy V.; Tremblay J. L.; Bertrand C.; Pelletier J. P.: Safety and efficacy of 
long-term intraarticular steroid injection in osteoarthritis of the knee: a randomized, 
double-blind, placebo-controlled trial. Arthritis Rheum. 48(2): 370-377，2003. 
Reynolds E. S.; Kanz F. M.; Chieco P.; Moslen M. T.: 1,1 -Dichloroethylene: an apoptotic 
hepatotoxin? Environ. Health Perspect. 57: 313-320,1984. 
Robinson M. J.; Cobb M. H.: Mitogen-activated protein kinase pathways. Curr. Opin. 
Cell Biol. 9 (2): 180-186，1997. 
Rodriguez J. and Lazebnik Y.: Caspase-9 and Apaf-1 form an active holoenzyme. Genes 
Dev. 13:3179-3184,1999. 
Rose U. M.; Bindels R. J.; Jansen J. W.; van Os C. H.: Effects of Ca^ "^  channel blockers, 
low Ca2+ medium and glycine on cell Ca2+ and injury in anoxic rabbit proximal tubules. 
Kidney Int. 46 (1): 223-229, 1994. 
Rudy B.: Diversity and ubiquity of K channels. Neuroscience 25 (3): 729-749,1988. 
Ruth P.; Rohrkasten A.; Biel M.; Bosse E.; Regulla S.; Meyer H. E.; Flockerzi V.; 
Hofmann R: Primary structure of the beta subunit of the DHP-sensitive calcium channel 
from skeletal muscle. Science 245 (4922): 1115-1118,1989. 
Saini J. S.; Gupta A.; Pandey S. K.; Gupta V.; Gupta P.: Efficacy of supratarsal 
dexamethasone versus triamcinolone injection in recalcitrant vernal keratoconjunctivitis. 
Acta. Ophthalmol. Scand. 77(5): 515-518,1999. 
Sakamoto T.; Miyazaka M.; Hisatomi T.; Nakamura T.; Ueno A.; Itaya K.; Ishibashi T.: 
116 
Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and 
decreases the postoperative blood-ocular barrier breakdown. Graefe's Arch. Clin. Exp. 
Ophthal. 240: 423-439，2002. 
SakuraH.; AmmalaC.; Smith P. A.; GribbleF. M. and Aschcroft F. M.: Cloning and 
functional expression of the cDNA encoding a novel ATP-sensitive potassium channel 
subunit expressed in pancreatic (3-cells，heart and skeletal muscle. FEBS Lett 377: 
338-344, 1995. 
Saleh A.; Srinivasula S. M.; Acharya S.; Fishel R. and Alnemri E. S.: Cytochrome C and 
dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J. 
Biol. Chem. 274: 17941-17945,1999. 
Salvesen G S. and Dixit V. M.: Caspases: intracellular signaling by proteolysis. Cell 91: 
443-446，1997. 
Sasaki S. and Kurisu K.: Effect of triamcinolone acetonide on proliferation and collagen 
and glycosaminoglycan synthesis in palatal mesenchymal cells from the mouse fetus. J. 
Craniofac. Genet. Dev. Biol. 3(4): 351-369,1983. 
Sato T.; Sasaki N.; Seharaseyon J.; O'Rourke B.; Marban E.: Selective pharmacological 
agents implicate mitochondrial but not sarcolemmal KATP channels in ischemic 
cardioprotection. Circ. 101: 2418-2423, 2000. 
Schaeffer H.; Weber M. J.: Mitogen-activated protein kinases: specific messages from 
ubiquitous messengers. Mol. Cellul. Bio. 2435-2444，1999. 
SchindlerR.H.; ChandlerD.; ThresherR.; MachemerR.: Theelearance ofintravitreal 
triamcinolone acetonide. Am. J. Ophthal. 93: 415-417，1982. 
Schleimer R. P.: An overview of glucocorticoids anti-inflammatory actions. Eur. J. Clin. 
Pharmacol. 45: S3-S7, 1993. 
Scholes G N.; O'Brien W. J.; Abrams G W.; Kubicek M. F. Clearance of triamcinolone 
from vitreous. Arch. Ophthal. 103: 1567-1569, 1985. 
Schraermeyer U. and Heimann K.: Current understanding on the role of retinal pigment 
epithelium and its pigmentation. Pigment Cell Res. 12 (4): 219-236，1999. 
117 
Scriabine A.: Current and potential indications for Ca2+ antagonists. Ration Drug Ther. 
21 (11): 1-7，1987. 
Searle J.; Kerr J. R; Bishop C. J.: Necrosis and apoptosis: distinct modes of cell death 
with fundamentally different significance. Pathol. Annu. 17: 229-259, 1982. 
Sebille S.; De Tullio P.; Boverie S.; Antoine M. H.; Lebmn P.; Pirotte B.: Recent 
developments in the chemistry of potassium channel activators: the cromakalim analogs. 
Curr. Med. Chem. 11(9): 1213-1222, 2004. 
Shaulian E. and Karin M.: AP-1 in cell proliferation and survival. Oncogene 20: 
2390-2400, 2001. 
Shaulian E.; Schreiber M.; Piu R; Beeche M.; Wagner E. R; Karin M.: The mammalian 
UV response: c-jun induction is required for exit from p53-imposed growth arrest. Cell 
103 (6): 897-907，2000. 
Sheidow T. G; Gonder J. R.: Cystoid macular edema following combined 
phacoemulsification and vitrectomy for macular hole. Retina. 18(6): 510-514，1998. 
Shi Y. G: Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell 9: 
459-470, 2002. 
Shunji Kusaka; Atsushi Inanobe; Akikazu Fujita; Yasunaka Makino; Masayuki Tanemoto; 
Kenji Matsushita; Yasuo Tano and Yoshihisa Kurachi: Functional KirT.l channels 
localized at the root of apical processes in rat retinal pigment epithelium. J. Physiology. 
531:27-36, 2001. 
Siemen D.; Loupatatzis C.; Borecky J.; Gulbins E. and Lang R: Ca^^-activated K channel 
of the BK-type in the inner mitochondrial membrane of a human glioma cell line. 
Biochem. Biophys. Res. Commun. 257: 549-554,1999 
Snodderly D. M.: E vidence f or p rotection a gainst a ge-related m acular d egeneration b y 
carotenoids and antioxidant vitamins. Am. J. Clin. Nutr. 62(suppl.)： 1148s-1161s，1995. 
Soares-da-Silva P.; Femandes M. H.: Inhibition by the putative potassium channel opener 
pinacidil of the electrically-evoked release of endogenous dopamine and noradrenaline in 
118 
the rat vas deferens. Naunyn Schmiedebergs Arch. Pharmacol. 342(4): 415-421, 1990. 
Somlyo A. P.; Somlyo A. V.: Smooth muscle: excitation-contraction coupling, contractile 
regulation, and the cross-bridge cycle. Alcohol. Clin. Exp. Res. 18: 138-143，1994. 
Standen N. B.; Quayle J. M.: K+ channel modulation in arterial smooth muscle. Acta. 
Physiol. Scand. 164 (4): 549-557,1998. 
Standen N. B.; Quayle J. M.; Davies N. W.; Brayden J. E.; Huang Y.; Nelson M. T.: 
Hyperpolarizing vasodilators activate ATP-sensitive K+ channels in arterial smooth 
muscle. Science 245(4914): 177-180，1989. 
Steinberg M. I.; Ertel P.; Smallwood J. K.; Wyss V.; Zimmerman K.: The relation between 
vascular relaxant and cardiac electrophysiological effects of pinacidil. J. Cardiovasc. 
Pharmacol. 12 Suppl. 2: S30-S40, 1988. 
Steinberg M. L; Wiest S. A.; Zimmerman K. M.; Ertel P. J.; Bemis K. G; Robertson D. W.: 
Chiral recognition of pinacidil and its 3-pyridyl isomer by canine cardiac and smooth 
muscle: antagonism by sulfonylureas. J. Pharmacol. Exp. Ther. 256(1): 222-229, 1991. 
Stockbridge N.; Zhang H.; Weir B.: Effects of K+ channel agonists cromakalim and 
2 + + 
pinacidil on rat basilar artery smooth muscle cells are mediated by Ca -activated K 
channels. Biochem. Biophys. Res. Commun. 181(1): 172-178,1991. 
Strauss O.; Richard G; Wienrich M.: Voltage-dependent potassium currents in cultured 
human retinal pigment epithelial cells. Biochem. Biophys Res. Commun. 191: 775-781, 
1993. 
Strauss O.; Buss R; Rosenthal R.; Fischer D.; Mergler S.; Stumpff R andThiemeH.: 
Activation of neuroendocrine L-type channels (alpha ID subunits) in retinal pigment 
epithelial cells and brainneurons b y p 0 6 0 � - ^ . Biochem. Biophys. Res. Commun. 270: 
806-810，2000. 
Strasser A.; O'Connor L. and Dixit V. M.: Apoptosis signaling. Annu. Rev. Biochem. 69: 
217-245’ 2000. 
Stmiskova M.; Barancik M.; Ravingerova T.: Mitogen-activated protein kinases and their 
role in regulation of cellular processes. Gen. Physiol. Biophys. 21(3): 231-255, 2002. 
119 
Szabo C.; Hasko G; Nemeth Z. H.; Vizi E. S.: Calcium entry blockers increase 
interleukin-lO production in endotoxemia. Shock 7 (4): 304-307，1997. 
Taira N.: Differences in cardiovascular profile among calcium antagonists. Am. J. Cardiol. 
59 (3): 24B-29B, 1987. 
Takahashi M.; Seagar M. J.; Jones J. R; Reber B. R; Catterall W. A.: Subunit structure of 
dihydropyridine-sensitive calcium channels from skeletal muscle. Proc. Natl. Acad. Sci. 
U. S. A. 84 (15): 5478-5482, 1987. 
Takahashi N.; Morishige K.; Jahangir A.; Yamada M.; Findlay I.; Koyama H. and Kurachi 
Y.: Molecular cloning and functional expression of cDNA encoding a second class of 
inward rectifier potassium channels in the mouse brain. J. Biol. Chem. 269: 23274-23279, 
1994. 
Takano T.; Soltoff S. P.; Murdaugh S.; Mandel L. J.: Intracellular respiratory dysfunction 
and cell injury in short-term anoxia of rabbit renal proximal tubules. J. Clin. Invest. 76 (6): 
2377-2384, 1985. 
Takano Y. S.; Harmon B. V.; Kerr J. R: Apoptosis induced by mild hyperthermia in 
human and murine tumor cell lines: a study using electron microscopy and DNA gel 
eletrophoresis. J. Pathol. 163: 329-336，1991. 
Takashi E.; Wang Y. and Ashraf M.: Activation of mitochondrial K (ATP) channel elicits 
late preconditioning against myocardial infarction via protein kinase C signaling pathway. 
Circ. Res. 85: 1113-1114, 1999. 
Takeuchi M.; Kaga M.; Tsuga T.; Ichinohe M.; Okazaki S.; Shinpo K.; Sudo J.; Tanabe T.: 
Study on toxicity of halopredone acetate. (I) Acute toxicity study in mice and rats. J. 
Toxicol. Sci. 10: suppl. 1: 1-10，1985. 
Takumi T.; Ishii T. ;Horio Y.; Morishige K.; Takahashi N.; Yamada M.; YamashitaT.; 
Koyama H. and Kurachi Y.: A novel ATP-dependent inward rectifier potassium channel 
expressed predominantly in glial cells. J. Biol. Chem. 270: 16339-16346,1995. 
Tanabe T.; Takeshima H.; Mikami A.; Flockerzi V.; Takahashi H.; Kangawa K.; Kojima 
M.; Matsuo H.; Hirose T.; Numa S.: Primary structure of the receptor for calcium channel 
blockers from skeletal muscle. Nature 328 (6128): 313-318，1987. 
120 
Tang T. L.; Dong C.; DufField R.; Ho Andrew K. S.: Protection of cardiomyocytes by 
pinacidil during metabolic inhibition and hyperkalemia. Eur. J. Pharmacol. 376: 179-187， 
1999. 
Tano Y.; Chandler D. B.; Machemer R.: Treatment of intraocular proliferation with 
intravitreal injection of triamcinolone acetonide. Am. J. Ophthal. 90: 810-816，1980. 
Tano Y.; Chandler D. B.; McCuen B. W.; Mchemer R.: Glucocorticosteroid inhibition of 
intraocular proliferation after injury. Am. J. Ophthal. 91: 184-189，1981. 
Tao Q.; Rafuse P. E.; Kelly MEM: Potassium currents in cultured rabbit retinal pigment 
epithelial cells. J. Membr. Biol. 141: 123-138,1994. 
Tao Q]; Kelly MEM: Calcium-activated potassium current in cultured rabbit retinal 
pigment epithelial cells. Curr. Eye. Res. 15: 237-246，1995. 
Teshima Y.; Ako M.; Li R.; Chong T. H.; Baumgartner W. A.; Johnston M. V.; Marb紐 E.: 
Mitochondrial ATP-sensitive potassium channel activation protects cerebellar granule 
neurons from apoptosis induced by oxidative stress. Stroke 34 (7): 1796-1802, 2003. 
Tewari M.; Quan L. T.; O'Rouke K.; Desnoyers S.; Zeng Z.; Beidler D. R.; Poirier G C.; 
Salvesen G S. and Dixit V. M. Cell 81: 801-809,1995. 
Thomberry N. A. and Lazebnik Y.: Caspases: enemies within. Science 281: 1312-1316, 
1998. 
Tominaga T.; Kure S.; Narisawa K.; Yoshimo T.: Endonuclease activation following focal 
ischemic injury in the rat brain. Brain Res. 608: 21-26, 1993. 
Tsang S. Y.; Yao X. Q.; Wong C. M.; Au C. L.; Chen Z. Y. and Huang Y.: Contribution of 
Na+ -Ca2+ exchanger to pinacidil-induced relaxation in the rat mesenteric artery. Br. J. 
Pharmacol. 138: 453-460, 2003. 
Twentyman PR.; Luscombe M.: A study of some variables in a tetrazolium dye (MTT) 
based assay for cell growth and chemosensitivity. Br. J. Cancer. 56 (3): 279-285,1987. 
Ueda S.; Masutani H.; Nakamura H.; Tanaka T.; Ueno M.; Yodoi J.: Redox control of cell 
121 
death. Antioxid. Redox. Signal 4 (3): 405-414, 2002. 
Uyama M.; Matsunaga H.; Matsubara T.; Fukushima L; Takahashi K. and Nishimura T.: 
Indocyanine green angiography and pathophysiology of multifocal posterior pigment 
epitheliopathy. Retina 19 (1): 12-21,1999. 
Valeric M.: The hazards of prolonged local cortisone therapy. Bull. Mem. Soc. Fr. 
Ophthalmol. 76: 572-580, 1963. 
Videbaek L. M.; Aalkjaer C.; Mulvany M. J.: Effect of pinacidil on norepinephrine- and 
potassium-induced contractions and membrane potential in rat and human resistance 
vessels and in rat aorta. J. Cardiovasc. Pharmacol. 12 Suppl. 2: S23-S29,1988. 
Vig E.; Barrett T. J. and Vedeckis W. V.: Coordinate regulation of glucocorticoid receptor 
and c-jun mRNA levels: evidence for cross-talk between two signaling pathways' at the 
transcriptional level. Mol. Endocrinol. 8 (10): 1336-1346，1994. 
Webster J. C.; Cidlowski J.: Mechanisms of glucocorticoid-receptor-mediated repression 
of gene expression. Trends Endocrinol. Metab. 10: 396-402, 1999. 
Weinstein D. B.; Heider J. G: Antiatherogenic properties of calcium antagonists. Am. J. 
Cardiol. 59 (3): 163B-172B, 1987. 
Wetzels J. R; Yu L.; Wang X.; Kribben A.; Burke T. J.; Schrier R. W.: Calcium 
modulation and cell injury in isolated rat proximal tubules. J. Pharmacol. Exp. Ther. 267 
(1): 176-180，1993. 
Whitmarsh A. J. and Davis R. J.: Transcription factor AP-1 regulation by 
mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 74: 589-607， 
1996. 
Wilkinson M. G; Millar J. B.: Control of the eukaryotic cell cycle by MAP kinase 
signaling pathways. FASEB J. 14: 2147-2157,2000. 
Willermain R; Caspers-Velu L.; Nowak B.; Stordeur P.; Mosselmans R.; Salmon I.; Velu 
T.; Bruyns C.: Retinal pigment epithelial cells phagocytosis of T lymphocytes: possible 
implication in the immune privilege of the eye. Br. J. Ophthalmol. 86 (12): 1417-1421, 
2002. 
122 
Wingate R. J. and Beaumont P. E.: Intravitreal triamcinolon and elevated intraocular 
pressure. Aust. N. Z. J. Ophthalmol. 27:431-432,1999. 
Wisdom R.; Johnson R. S.; Moore C.: c-jun regulates cell cycle progression and apoptosis 
by distinct mechanisms. EMBO J. 18 (1): 188-197，1999. 
Woodfork K. A.; Wonderlin W. R; Peterson V. A. and Strobl J. S.: Inhibition of 
ATP-sensitive potassium channels causes reversible cell-cycle arrest of human breast 
cancer cells in tissue culture. J. Cell. Physiol. 162: 163-171，1995. 
Wyllie A. H.; Kerr J. R; Currie A. R.: Cell death: the significance of apoptosis. Int. Rev. 
Cytol. 68: 251-306，1980. 
Xu W.; Liu Y.; Wang S.; McDonald T.; Van Eyk J. E.; Sidor A.; O'Rourke B.: 
Cytoprotective role of Ca^ "^ - activated K+ channels in the cardiac inner mitochondrial 
membrane. Science 298(5595): 1029-1033, 2002. 
Yamada M.; Isomoto S.; Matsumoto S.; Kondo C.; Shindo C.; Shindo T.; Horio Y. and 
Kurachi Y.: Sulfonylurea receptor 2B and Kir6.1 from a sulfonylurea-sensitive but 
ATP-insensitive K+ channel. J. Physiol. (Lond) 499: 715-720, 1997. 
Yeung C. K.; Chan K. P.; Chiang W. Y.; Pang C. P. and Dennis Lam S. C.: The toxic and 
stress responses of cultured human retinal pigment epithelium (ARPE 19) and human glial 
cells (SVG) in the presence of triamcinolone. Invest. Ophthalnol. Vis. Sci. 44: 5293-5300, 
2003. 
Yam H. R; Kwok K. O.; Chan K. P.; Lai Y. Y.; Chu K. Y.; Lam S. C. and Pang C. P.: 
Effect of indocyanine green and illumination on gene expression in human retinal 
pigment epithelial cells. Invest. Opthalmol. Vis. Sci. 44: 370-377, 2003. 
Yoshikawa K.; Kotade S.; Ichiishi A.; Sasamoto Y.; Kosaka S.; MatsudaH.: Posterior 
sub-Tenon injections if repository corticosteroids in uveitis patients with cystoid macular 
edema. Jpn. J.Ophthal. 39(1): 71-76，1995. 
Yuan J. Y.; Lipinski M.; Degterev A.: Diversity in the mechanisms of neuronal cell death. 
Neuron 40: 401-413’ 2003. 
123 
Yuan J.; Shaham S.; Ledoux S.; Ellis H. M. and Horvitz H. R.: The C. elegans cell death 
gene Ced-3 encodes a protein similar to mammalian interieukin-1 beta-converting 
enzyme. Cell 75: 641-652, 1993. 
Zaugg M.; Lucchinetti E.; Uecher M.; Pasch T.; Schaub M. C : Anaesthetics and cardiac 
preconditioning. Part I. Signalling and cytoprotective mechanisms. Bri. J. Anaesth. 91: 
551-565,2003. 
Zemir E.; Read R. W.; Smith R. E.; Wang R. C.; Rao N. A.: A prospective evaluation of 
subconjunctival injection of triamcinolone acetonide for resistant anterior scleritis. 
Ophthal. 109(4) 798-805; discussion 805-807, 2002. 
Zou H.; Li Y.; Liu X.; Wang X.: An APAF-1-cytochrome C multimeric complex is a 






• ：： ，if 
• ； < 
. — 
• ’ , • ！ 
•..；；" 
-.VI 
> • r ? 
• • m 
； : | | 
CUHK Libraries 
llllllllllll _ 
0QmMMM7A 
